MCID: GRV001
MIFTS: 54

Graves' Disease

Categories: Cancer diseases, Endocrine diseases, Immune diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Graves' Disease

MalaCards integrated aliases for Graves' Disease:

Name: Graves' Disease 11 42 75 14
Graves Disease 11 19 42 28 53 43 16 71
Exophthalmic Goiter 11 19 42
Toxic Diffuse Goiter 42 71
Basedow's Disease 11 42
Grave's Disease 11 14
Basedow Disease 19 42
Autoimmune Hyperthyroidism 42
Toxic Multinodular Goiter 71
Graves' Hyperthyroidism 19
Parry Disease 19

Classifications:



External Ids:

Disease Ontology 11 DOID:12361
MeSH 43 D006111
NCIt 49 C3071
SNOMED-CT 68 154655004
ICD10 31 E05.0
UMLS 71 C0018213 C0154143 C0342122

Summaries for Graves' Disease

MedlinePlus Genetics: 42 Graves disease is a condition that affects the function of the thyroid, which is a butterfly-shaped gland in the lower neck. The thyroid makes hormones that help regulate a wide variety of critical body functions. For example, thyroid hormones influence growth and development, body temperature, heart rate, menstrual cycles, and weight. In people with Graves disease, the thyroid is overactive and makes more hormones than the body needs. The condition usually appears in mid-adulthood, although it may occur at any age.Excess thyroid hormones can cause a variety of signs and symptoms. These include nervousness or anxiety, extreme tiredness (fatigue), a rapid and irregular heartbeat, hand tremors, frequent bowel movements or diarrhea, increased sweating and difficulty tolerating hot conditions, trouble sleeping, and weight loss in spite of an increased appetite. Affected women may have menstrual irregularities, such as an unusually light menstrual flow and infrequent periods. Some people with Graves disease develop an enlargement of the thyroid called a goiter. Depending on its size, the enlarged thyroid can cause the neck to look swollen and may interfere with breathing and swallowing.Between 25 and 50 percent of people with Graves disease have eye abnormalities, which are known as Graves ophthalmopathy. These eye problems can include swelling and inflammation, redness, dryness, puffy eyelids, and a gritty sensation like having sand or dirt in the eyes. Some people develop bulging of the eyes caused by inflammation of tissues behind the eyeball and "pulling back" (retraction) of the eyelids. Rarely, affected individuals have more serious eye problems, such as pain, double vision, and pinching (compression) of the optic nerve connecting the eye and the brain, which can cause vision loss.A small percentage of people with Graves disease develop a skin abnormality called pretibial myxedema or Graves dermopathy. This abnormality causes the skin on the front of the lower legs and the tops of the feet to become thick, lumpy, and red. It is not usually painful.

MalaCards based summary: Graves' Disease, also known as graves disease, is related to graves disease 1 and exophthalmos. An important gene associated with Graves' Disease is GRD2 (Graves Disease, Susceptibility To, 2), and among its related pathways/superpathways are Cytokine Signaling in Immune system and NF-kappaB Signaling. The drugs Methimazole and Prednisolone phosphate have been mentioned in the context of this disorder. Affiliated tissues include thyroid gland, thyroid and eye, and related phenotypes are endocrine/exocrine gland and immune system

GARD: 19 Graves' disease is an autoimmune disorder that leads to overactivity of the thyroid gland (hyperthyroidism). It is caused by the immune system mistakenly attacking the thyroid gland, causing the gland to produce too much thyroid hormone. Graves disease is the most common cause of hyperthyroidism and occurs most often in women over age 20. However, the disorder may occur at any age and can affect males as well. More common signs and symptoms of hyperthyroidism due to Graves' disease include irritability, a fast and irregular heartbeat, hand tremors, diarrhea, increased sweating, trouble sleeping, and weight loss. Some people develop abnormal enlargement of the thyroid gland (goiter). Women with Graves' disease may have irregular menstrual periods. In some cases, Graves' disease causes other problems such as Graves' dermopathy (a condition marked by red, swollen skin), various eye abnormalities (such as bulging eyes, vision problems, pain, or swelling), emotional or behavioral changes, heart-related complications, or bone problems (such as osteoporosis).

Disease Ontology: 11 An autoimmune disease of endocrine system that involves production of excessive amount of thyroid hormones, located in thyroid gland.

Wikipedia: 75 Graves' disease (German: Morbus Basedow), also known as toxic diffuse goiter, is an autoimmune disease... more...

Related Diseases for Graves' Disease

Diseases in the Graves' Disease family:

Graves Disease 1 Graves Disease 2

Diseases related to Graves' Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 1047, show less)
# Related Disease Score Top Affiliating Genes
1 graves disease 1 33.4 TSHR TPO TG GRD1 DIO2
2 exophthalmos 32.6 TSHR TPO TG
3 hyperthyroidism 32.6 TSHR TPO TG LMOD1 GNAS CTLA4
4 myxedema 32.4 TSHR TPO TG CTLA4
5 endocrine exophthalmos 32.3 TSHR TPO TG
6 thyrotoxic exophthalmos 32.2 TSHR TPO TG CD40
7 graves ophthalmopathy 32.1 TSHR TG LMOD1 IFNG ICAM1 CTLA4
8 goiter 32.1 TSHR TPO TG GNAS
9 thyroiditis 32.1 TSHR TPO TG PTPN22 IL4 IFNG
10 hypothyroidism, congenital, nongoitrous, 1 32.0 TSHR TG GNAS
11 hypothyroidism 32.0 TSHR TPO TG PTPN22 IL4 GNAS
12 hashimoto thyroiditis 31.8 TSHR TPO TG PTPN22 LMOD1 IL4
13 subacute thyroiditis 31.7 TSHR TPO TG
14 thyroid crisis 31.7 TSHR TPO TG
15 nodular goiter 31.7 TSHR TPO TG ICAM1 CTLA4
16 nontoxic goiter 31.7 TSHR TPO TG
17 autoimmune disease 31.6 TSHR TPO TG PTPN22 IL4 IL2RA
18 plummer's disease 31.5 TSHR TPO TG ICAM1
19 eye disease 31.5 TSHR LMOD1 IL4 IFNG ICAM1 CTLA4
20 type 1 diabetes mellitus 31.5 TPO TG PTPN22 IL4 IFNG ICAM1
21 myasthenia gravis 31.4 PTPN22 IL4 IFNG CTLA4
22 hypoparathyroidism 31.4 TPO GNAS CTLA4
23 postsurgical hypothyroidism 31.4 TSHR TPO TG
24 neonatal thyrotoxicosis 31.3 TSHR TG
25 multinodular goiter 31.3 TSHR TPO TG GNAS
26 hypoadrenocorticism, familial 31.3 TPO TG PTPN22 CTLA4
27 thyroid gland follicular carcinoma 31.2 TSHR TPO TG
28 exanthem 31.2 IL4 IFNG CTLA4
29 autoimmune hepatitis 31.2 TPO PTPN22 IFNG CTLA4
30 vitiligo-associated multiple autoimmune disease susceptibility 1 31.2 TPO TG PTPN22 CTLA4
31 papillary carcinoma 31.1 TSHR TPO TG GNAS
32 goiter, multinodular 1, with or without sertoli-leydig cell tumors 31.1 TPO TG
33 pernicious anemia 31.1 TPO TG PTPN22
34 turner syndrome 31.1 TPO TG PTPN22
35 uveitis 31.0 IL4 IL2RA IFNG ICAM1 CTLA4
36 alopecia 31.0 IL4 IFNG CTLA4
37 celiac disease 1 30.9 TPO TG PTPN22 IL4 IL2RA IFNG
38 viral infectious disease 30.9 IL4 IL2RA IFNG ICAM1 CTLA4
39 allergic rhinitis 30.9 IL4 IL16 IFNG ICAM1
40 myocarditis 30.8 IL4 IFNG ICAM1 CTLA4
41 chronic urticaria 30.8 TPO TG PTPN22
42 toxic diffuse goiter 30.8 TSHR TPO TG
43 schistosomiasis 30.8 IL4 IFNG CTLA4
44 autoimmune gastritis 30.8 TPO TG CTLA4
45 immune deficiency disease 30.8 IL4 IL2RA IL16 IFNG CTLA4 CD40
46 thyroid hormone resistance, generalized, autosomal dominant 30.8 TSHR TG DIO2
47 severe combined immunodeficiency 30.7 IL4 IL2RA IFNG CTLA4 CD40
48 systemic lupus erythematosus 30.7 TPO PTPN22 IL4 IL2RA IL16 IFNG
49 sjogren syndrome 30.7 IL2RA ICAM1 CD40
50 congenital hypothyroidism 30.7 TSHR TPO TG GNAS DIO2
51 acute thyroiditis 30.7 TPO TG CTLA4
52 hepatitis a 30.7 IL4 IFNG CTLA4
53 connective tissue disease 30.7 IL4 IFNG ICAM1 HLA-DQA1 CTLA4 CD40
54 chronic spontaneous urticaria 30.7 TPO TG IL4
55 follicular adenoma 30.6 TSHR TPO TG GNAS DIO2
56 thyroid lymphoma 30.6 TPO TG
57 vogt-koyanagi-harada disease 30.6 PTPN22 IL2RA HLA-DQA1 CTLA4
58 arthritis 30.6 PTPN22 IL4 IL2RA IFNG FCRL3 CTLA4
59 rheumatoid arthritis 30.6 PTPN22 IL4 IL2RA IL16 IFNG ICAM1
60 suppurative thyroiditis 30.6 TSHR TPO TG
61 relapsing-remitting multiple sclerosis 30.5 IL4 IL2RA IFNG ICAM1
62 asthma 30.5 IL4 IL2RA IL16 IFNG ICAM1 HLA-DQA1
63 endemic goiter 30.5 TSHR TPO TG
64 subacute sclerosing panencephalitis 30.5 IL4 IFNG CTLA4
65 conjunctivitis 30.5 IL4 IL2RA IL16 IFNG ICAM1
66 multiple sclerosis 30.4 PTPN22 IL4 IL2RA IL16 IFNG ICAM1
67 diabetes mellitus 30.4 TPO TG PTPN22 IL4 IL2RA IFNG
68 lymphopenia 30.4 PTPN22 IL4 IL2RA IFNG CTLA4
69 lymphadenitis 30.4 IL2RA IFNG ICAM1
70 bone inflammation disease 30.4 PTPN22 IL4 IFNG CTLA4
71 iodine hypothyroidism 30.4 TSHR TPO TG
72 cholangitis 30.3 ICAM1 HLA-DQA1 CTLA4
73 crohn's disease 30.3 PTPN22 IL4 IFNG CTLA4 CEP43 CD40
74 orbital plasma cell granuloma 30.3 TSHR TPO TG CTLA4
75 viral hepatitis 30.3 TSHR TPO TG IL4 IFNG ICAM1
76 type 1 diabetes mellitus 5 30.3 TG PTPN22 HLA-DQA1 CTLA4
77 scleritis 30.3 PTPN22 IL4 IFNG CTLA4
78 miliary tuberculosis 30.3 IL4 IFNG
79 erythema nodosum 30.3 IFNG ICAM1 CTLA4
80 type 1 diabetes mellitus 12 30.2 HLA-DQA1 CTLA4
81 rheumatic fever 30.2 IFNG ICAM1 HLA-DQA1
82 alopecia areata 30.2 TPO PTPN22 IL4 IL2RA IFNG ICAM1
83 keratoconjunctivitis 30.2 IL4 IFNG ICAM1
84 smallpox 30.2 IL4 IFNG ICAM1
85 proteasome-associated autoinflammatory syndrome 1 30.2 IL4 IFNG ICAM1
86 pulmonary sarcoidosis 30.2 IL2RA IFNG ICAM1
87 acute graft versus host disease 30.2 IL2RA IFNG
88 temporal arteritis 30.2 PTPN22 IL4 IFNG ICAM1 CTLA4
89 lagophthalmos 30.2 TSHR TG
90 behcet syndrome 30.2 PTPN22 IL4 IL2RA IFNG ICAM1 HLA-DQA1
91 human immunodeficiency virus infectious disease 30.2 IL4 IL2RA IL16 IFNG
92 allergic asthma 30.2 IL4 IL16 IFNG ICAM1 CTLA4
93 juvenile rheumatoid arthritis 30.2 PTPN22 IL2RA HLA-DQA1
94 malaria 30.1 IL4 IL2RA IFNG ICAM1 CTLA4 CD40
95 combined immunodeficiency 30.1 IL4 IL2RA IFNG ICAM1 CTLA4 CD40
96 periodontitis 30.0 IL4 IFNG ICAM1
97 dermatitis, atopic 30.0 IL4 IL2RA IL16 IFNG ICAM1 CTLA4
98 tetanus 30.0 IL4 IL2RA IFNG
99 skin disease 30.0 IL4 IFNG ICAM1 CTLA4 CD40
100 thyroid gland disease 29.9 TSHR TPO TG GNAS DIO2 CTLA4
101 graves disease x-linked 1 11.4
102 graves disease 2 11.4
103 thyrotoxic myopathy 11.2
104 autoimmune thyroid disease 3 11.1
105 methimazole antenatal exposure 11.1
106 hypothyroidism, congenital, nongoitrous, 2 11.1
107 hypothyroidism, congenital, nongoitrous, 3 11.1
108 moyamoya disease 1 11.1
109 ceroid lipofuscinosis, neuronal, 4 11.1
110 pediatric-onset graves disease 11.1
111 hyperthyroidism, nonautoimmune 11.1
112 digeorge syndrome 11.0
113 chromosome 22q11.2 deletion syndrome, distal 11.0
114 orthostatic intolerance 11.0
115 thyrotoxic periodic paralysis 1 11.0
116 thyrotoxic periodic paralysis 2 11.0
117 autoimmune thyroid disease 2 11.0
118 velocardiofacial syndrome 11.0
119 thyroid carcinoma 10.9
120 orbital disease 10.7
121 thyroid cancer, nonmedullary, 1 10.6
122 periodic paralysis 10.6
123 rickets 10.6
124 vasculitis 10.6
125 granulocytopenia 10.6
126 tremor 10.6
127 optic nerve disease 10.5
128 hypokalemia 10.5
129 adenoma 10.5
130 mechanical strabismus 10.5 TPO TG
131 adult-onset myasthenia gravis 10.5 HLA-DQA1 CTLA4
132 thyrotoxic periodic paralysis 10.5
133 subacute lymphocytic thyroiditis 10.5 TSHR TPO TG
134 thyroid dyshormonogenesis 2a 10.5 TSHR TPO TG
135 purpura 10.5
136 chronic orbital inflammation 10.5 TSHR TPO TG CTLA4
137 hypotropia 10.5 TSHR TPO
138 nonencapsulated sclerosing carcinoma 10.5 TPO TG
139 thrombocytopenia due to platelet alloimmunization 10.5
140 49, xxxxy syndrome 10.5
141 49,xxxxx syndrome 10.5
142 49,xyyyy syndrome 10.5
143 familial thyroid dyshormonogenesis 10.5 TPO TG DIO2
144 adrenal cortex disease 10.5 TPO TG PTPN22 CTLA4
145 hyperglobulinemic purpura 10.5 IFNG ICAM1
146 rheumatoid factor-negative polyarticular juvenile idiopathic arthritis 10.5 PTPN22 IL2RA
147 autoimmune disease of exocrine system 10.5 IL4 CTLA4 CD40
148 chickenpox 10.5 IL4 IFNG CTLA4
149 oligoarticular juvenile idiopathic arthritis 10.5 PTPN22 IL2RA
150 down syndrome 10.5
151 aplastic anemia 10.5
152 myopathy 10.5
153 primary agammaglobulinemia 10.5
154 paracoccidioidomycosis 10.5 IL4 IFNG CTLA4
155 b cell deficiency 10.5 IL4 CTLA4 CD40
156 autoimmune disease of cardiovascular system 10.4 IL4 IFNG CTLA4
157 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 10.4 IL4 IL2RA CTLA4
158 coccidiosis 10.4 IL4 IFNG CD40
159 hypersensitivity reaction type iv disease 10.4 IL4 IFNG CTLA4
160 tuberculoid leprosy 10.4 IL4 IL2RA IFNG
161 filariasis 10.4 IL4 IFNG CTLA4
162 thyrotropin-releasing hormone deficiency 10.4
163 hyperparathyroidism 10.4
164 lichen disease 10.4 IL4 IFNG ICAM1
165 erythema multiforme 10.4 IL4 IFNG ICAM1
166 primary bacterial infectious disease 10.4 IL4 IFNG CTLA4 CD40
167 leishmaniasis 10.4 IL4 IFNG CTLA4 CD40
168 adrenal cortical hypofunction 10.4 TPO TG PTPN22 HLA-DQA1 CTLA4
169 dermatitis 10.4 IL4 IL16 IFNG CTLA4
170 fuchs' heterochromic uveitis 10.4 IL2RA IFNG
171 leptospirosis 10.4 IL4 IFNG ICAM1
172 neuromyelitis optica 10.4 IL4 HLA-DQA1 CD40
173 autoimmune disease of gastrointestinal tract 10.4 IL4 IFNG HLA-DQA1 CTLA4
174 extrinsic cardiomyopathy 10.4 IL4 IFNG ICAM1 CTLA4
175 uveal disease 10.4 IL4 IFNG ICAM1 CTLA4
176 glomerulonephritis 10.4
177 autoimmune disease of skin and connective tissue 10.4 IL4 IFNG ICAM1 CTLA4
178 skin sarcoidosis 10.4 IFNG CTLA4
179 nose disease 10.4 IL4 IFNG ICAM1
180 sezary's disease 10.4 IL4 IL2RA IFNG CTLA4
181 parasitic protozoa infectious disease 10.4 IL4 IFNG ICAM1 CD40
182 leprosy 3 10.4 IL4 IFNG HLA-DQA1
183 integumentary system disease 10.4 IL4 IFNG ICAM1 CTLA4
184 rubella 10.4 IL4 IL2RA IFNG HLA-DQA1
185 thrombocytopenic purpura, autoimmune 10.4
186 pancytopenia 10.4
187 toxoplasmosis 10.4 IL4 IFNG HLA-DQA1
188 gingivitis 10.4 IL4 IFNG ICAM1
189 esophageal tuberculosis 10.4 IL2RA IFNG
190 autoimmune disease of central nervous system 10.4 IL4 IFNG ICAM1 CTLA4 CD40
191 chagas disease 10.4 IL4 IFNG CTLA4
192 bronchiolitis 10.4 IL4 IFNG ICAM1
193 severe acute respiratory syndrome 10.4
194 lichen planus 10.4 IL4 IFNG ICAM1
195 hemophagocytic lymphohistiocytosis 10.4 IL2RA IFNG CTLA4
196 visceral leishmaniasis 10.4 IL4 IL2RA IFNG
197 deficiency anemia 10.4
198 pulmonary hypertension 10.4
199 arteriosclerosis 10.4 IL4 IFNG ICAM1 CD40
200 primary cutaneous t-cell non-hodgkin lymphoma 10.4 IL4 IL2RA IFNG
201 allergic contact dermatitis 10.4 IL4 IFNG ICAM1
202 mycoplasma pneumoniae pneumonia 10.4 IL4 IFNG
203 common variable immunodeficiency 10.4 IL4 IL2RA IFNG CTLA4 CD40
204 thrombocytopenia 10.4
205 mycosis fungoides 10.4 IL4 IL2RA IL16 IFNG CTLA4
206 autoimmune disease of musculoskeletal system 10.4 PTPN22 IL4 IFNG ICAM1 CTLA4 CD40
207 pulmonary tuberculosis 10.4 IL4 IL2RA IFNG
208 necrotizing gastritis 10.4 TPO CTLA4
209 gaucher disease, type i 10.4
210 struma ovarii 10.4
211 hypoglycemia 10.4
212 bronchial disease 10.3 IL4 IFNG ICAM1
213 cytokine deficiency 10.3
214 lymphoid interstitial pneumonia 10.3 IL4 IFNG CTLA4
215 hypokalemic periodic paralysis, type 1 10.3
216 vitiligo-associated multiple autoimmune disease susceptibility 6 10.3
217 neutropenia 10.3
218 cholestasis 10.3
219 diphtheria 10.3 IL4 IL2RA IFNG
220 leukocyte disease 10.3 IL4 IFNG CTLA4
221 chondromalacia 10.3 IFNG HLA-DQA1
222 strabismus 10.3
223 thyroid cancer, nonmedullary, 2 10.3
224 neuropathy 10.3
225 encephalopathy 10.3
226 hypercalcemia, infantile, 1 10.3
227 systemic lupus erythematosus 1 10.3
228 premature ovarian failure 7 10.3
229 anca-associated vasculitis 10.3
230 psoriasis 10.3 PTPN22 IL4 IL2RA IFNG ICAM1 CTLA4
231 lymphoma, hodgkin, classic 10.3
232 hirata disease 10.3
233 ptosis 10.3
234 primary hyperparathyroidism 10.3
235 autoimmune polyendocrine syndrome 10.3
236 urticaria 10.3
237 hepatitis c 10.3
238 systemic scleroderma 10.3
239 lymphoproliferative syndrome 1 10.3 IL2RA IL16
240 tatton-brown-rahman syndrome 10.3
241 bone resorption disease 10.3
242 covid-19 10.3
243 pituitary adenoma 10.3
244 congestive heart failure 10.3
245 differentiated thyroid carcinoma 10.3
246 ovarian cystadenocarcinoma 10.3 SLC25A16 GNAS CTLA4
247 thyroid carcinoma, familial medullary 10.2
248 sarcoidosis 1 10.2
249 sarcoidosis 2 10.2
250 prediabetes syndrome 10.2
251 hepatitis 10.2
252 lupus erythematosus 10.2
253 renal cell carcinoma, nonpapillary 10.2 SLC25A16 IL4 IL2RA IFNG ICAM1 CTLA4
254 inflammatory bowel disease 10.2 PTPN22 IL4 IL2RA IL16 IFNG ICAM1
255 autoimmune disease of endocrine system 10.2 TSHR TPO TG PTPN22 IL4 IL2RA
256 scleroderma, familial progressive 10.2
257 pulmonary fibrosis and/or bone marrow failure, telomere-related, 2 10.2
258 pericardial effusion 10.2
259 nephrotic syndrome 10.2
260 conn's syndrome 10.2
261 allergic disease 10.2
262 primary biliary cholangitis 10.2
263 gynecomastia 10.2
264 hemolytic anemia 10.2
265 thrombophilia due to thrombin defect 10.2
266 anemia, autoimmune hemolytic 10.2
267 gaucher disease, type ii 10.2
268 kearns-sayre syndrome 10.2
269 papillary thyroid microcarcinoma 10.2
270 hyperthyroxinemia 10.2
271 thymoma 10.2
272 hashimoto encephalopathy 10.2
273 osteoporosis 10.2
274 stroke, ischemic 10.2
275 membranous nephropathy 10.2
276 lipoprotein quantitative trait locus 10.2
277 thrombosis 10.2
278 polymyositis 10.2
279 thrombotic thrombocytopenic purpura 10.2
280 respiratory failure 10.2
281 secondary hyperparathyroidism 10.2
282 crescentic glomerulonephritis 10.2
283 amenorrhea 10.2
284 pericarditis 10.2
285 hypogonadism 10.2
286 transient cerebral ischemia 10.2
287 acromegaly 10.2
288 rhinitis 10.2
289 chronic kidney disease 10.2
290 chronic rhinitis 10.2
291 hypopituitarism 10.2
292 familial hyperthyroidism due to mutations in tsh receptor 10.2
293 type 2 diabetes mellitus 10.1
294 factor viii deficiency 10.1
295 keratitis, hereditary 10.1
296 iga nephropathy 1 10.1
297 camptodactyly-arthropathy-coxa vara-pericarditis syndrome 10.1
298 ventricular fibrillation, paroxysmal familial, 1 10.1
299 hyperprolactinemia 10.1
300 igg4-related disease 10.1
301 hypogonadotropic hypogonadism 10.1
302 dermatomyositis 10.1
303 common cold 10.1
304 glucose intolerance 10.1
305 dilated cardiomyopathy 10.1
306 diarrhea 10.1
307 obstructive jaundice 10.1
308 angioedema 10.1
309 thyroid gland cancer 10.1
310 psychotic disorder 10.1
311 gastric antral vascular ectasia 10.1
312 iga glomerulonephritis 10.1
313 liver disease 10.1
314 liver cirrhosis 10.1
315 parathyroid adenoma 10.1
316 47 xxx syndrome 10.1
317 central congenital hypothyroidism 10.1
318 autoimmune addison disease 10.1
319 systemic autoimmune disease 10.1
320 hypothyroidism, congenital, nongoitrous, 4 10.1 TPO TG
321 stiff-person syndrome 10.1
322 hypoascorbemia 10.1
323 ocular motor apraxia 10.1
324 insulin-like growth factor i 10.1
325 anxiety 10.1
326 muscle hypertrophy 10.1
327 angina pectoris 10.1
328 atrial fibrillation 10.1
329 lipoid nephrosis 10.1
330 henoch-schoenlein purpura 10.1
331 mitral valve insufficiency 10.1
332 quadriplegia 10.1
333 choreatic disease 10.1
334 keratopathy 10.1
335 bilirubin metabolic disorder 10.1
336 subacute delirium 10.1
337 pulmonary embolism 10.1
338 esotropia 10.1
339 growth hormone deficiency 10.1
340 human t-cell leukemia virus type 1 10.1
341 splenomegaly 10.1
342 pituitary tumors 10.1
343 euthyroid graves orbitopathy 10.1
344 chronic bilirubin encephalopathy 10.1
345 arteries, anomalies of 10.0
346 pheochromocytoma 10.0
347 tobacco addiction 10.0
348 pituitary hormone deficiency, combined, 2 10.0
349 gitelman syndrome 10.0
350 inflammatory bowel disease 1 10.0
351 autoimmune polyendocrine syndrome, type ii 10.0
352 ataxia with vitamin e deficiency 10.0
353 helicobacter pylori infection 10.0
354 hepatitis c virus 10.0
355 bone mineral density quantitative trait locus 8 10.0
356 bone mineral density quantitative trait locus 15 10.0
357 leptin deficiency or dysfunction 10.0
358 hyperlipoproteinemia, type iii 10.0
359 atrioventricular block 10.0
360 third-degree atrioventricular block 10.0
361 colitis 10.0
362 cardiac arrest 10.0
363 autoimmune myocarditis 10.0
364 central diabetes insipidus 10.0
365 pre-eclampsia 10.0
366 open-angle glaucoma 10.0
367 premature menopause 10.0
368 pulmonary edema 10.0
369 guillain-barre syndrome 10.0
370 vascular disease 10.0
371 craniosynostosis 10.0
372 iron metabolism disease 10.0
373 spinal cord disease 10.0
374 acute myocarditis 10.0
375 thyroid gland medullary carcinoma 10.0
376 gastritis 10.0
377 tricuspid valve insufficiency 10.0
378 malignant struma ovarii 10.0
379 functioning pituitary adenoma 10.0
380 kidney disease 10.0
381 t-cell acute lymphoblastic leukemia 10.0
382 adrenal adenoma 10.0
383 cerebrovascular disease 10.0
384 ulcerative colitis 10.0
385 evans' syndrome 10.0
386 diabetes insipidus 10.0
387 hypersensitivity vasculitis 10.0
388 pik3ca-related overgrowth spectrum 10.0
389 48,xxxy syndrome 10.0
390 48,xxyy syndrome 10.0
391 48,xyyy 10.0
392 inherited thyroxine-binding globulin deficiency 10.0
393 drug-induced vasculitis 10.0
394 pik3ca-related overgrowth syndrome 10.0
395 acute adrenal insufficiency 10.0
396 basedow's coma 10.0
397 burkitt lymphoma 10.0
398 guillain-barre syndrome, familial 10.0
399 attention deficit-hyperactivity disorder 10.0
400 hypogonadotropic hypogonadism 7 with or without anosmia 10.0
401 myositis 10.0
402 neurofibromatosis, type i 10.0
403 oculodentodigital dysplasia 10.0
404 polycystic liver disease 1 with or without kidney cysts 10.0
405 polycystic ovary syndrome 1 10.0
406 gaucher disease, type iii 10.0
407 autoimmune polyendocrine syndrome, type i, with or without reversible metaphyseal dysplasia 10.0
408 congenital hemidysplasia with ichthyosiform erythroderma and limb defects 10.0
409 neurofibromatosis-noonan syndrome 10.0
410 human immunodeficiency virus type 1 10.0
411 diabetes mellitus, ketosis-prone 10.0
412 graft-versus-host disease 10.0
413 hemorrhage, intracerebral 10.0
414 leukemia, acute lymphoblastic 3 10.0
415 disease by infectious agent 10.0
416 autoimmune polyendocrine syndrome type 1 10.0
417 hypophosphatemia 10.0
418 aphasia 10.0
419 b-lymphoblastic leukemia/lymphoma 10.0
420 pemphigoid 10.0
421 heart disease 10.0
422 polycystic ovary syndrome 10.0
423 iron deficiency anemia 10.0
424 myopia 10.0
425 coronary artery vasospasm 10.0
426 optic neuritis 10.0
427 filarial elephantiasis 10.0
428 generalized anxiety disorder 10.0
429 candidiasis 10.0
430 personality disorder 10.0
431 neuritis 10.0
432 hyperinsulinism 10.0
433 endometriosis 10.0
434 acute pancreatitis 10.0
435 antiphospholipid syndrome 10.0
436 multiple endocrine neoplasia 10.0
437 teratoma 10.0
438 bipolar disorder 10.0
439 mood disorder 10.0
440 mixed connective tissue disease 10.0
441 craniopharyngioma 10.0
442 insulinoma 10.0
443 movement disease 10.0
444 elephantiasis 10.0
445 pancreatitis 10.0
446 tsh producing pituitary tumor 10.0
447 bullous pemphigoid 10.0
448 neurofibromatosis 10.0
449 pemphigus 10.0
450 ocular hypertension 10.0
451 dextrocardia 10.0
452 autoimmune polyglandular syndrome type 3 10.0
453 children's interstitial lung disease 10.0
454 chronic graft versus host disease 10.0
455 leukemia, t-cell, chronic 10.0
456 syncope 10.0
457 functional neutrophil defect 10.0
458 fetal anticonvulsant syndrome 10.0
459 polyendocrinopathy 10.0
460 keloid disorder 10.0
461 amyotrophic lateral sclerosis 1 9.9
462 spondyloarthropathy 1 9.9
463 carpal tunnel syndrome 9.9
464 multiple endocrine neoplasia, type i 9.9
465 ige responsiveness, atopic 9.9
466 myotonic dystrophy 1 9.9
467 neutrophilia, hereditary 9.9
468 noonan syndrome 1 9.9
469 teratoma, ovarian 9.9
470 ovarian cancer 9.9
471 pulmonary hypertension, primary, 1 9.9
472 dowling-degos disease 1 9.9
473 wolff-parkinson-white syndrome 9.9
474 lipoid congenital adrenal hyperplasia 9.9
475 ascites, chylous 9.9
476 factor vii deficiency 9.9
477 dubin-johnson syndrome 9.9
478 intracranial hypertension, idiopathic 9.9
479 papillon-lefevre syndrome 9.9
480 neuraminidase deficiency 9.9
481 rhabdomyosarcoma 2 9.9
482 asplenia, isolated congenital 9.9
483 thyroid hormone resistance, generalized, autosomal recessive 9.9
484 adrenoleukodystrophy 9.9
485 aland island eye disease 9.9
486 epilepsy, idiopathic generalized 9.9
487 langerhans cell histiocytosis 9.9
488 anorexia nervosa 9.9
489 bone mineral density quantitative trait locus 3 9.9
490 bulimia nervosa 9.9
491 prekallikrein deficiency 9.9
492 microvascular complications of diabetes 5 9.9
493 macs syndrome 9.9
494 mononeuropathy of the median nerve, mild 9.9
495 metabolic crises, recurrent, with rhabdomyolysis, cardiac arrhythmias, and neurodegeneration 9.9
496 arrhythmogenic right ventricular cardiomyopathy 9.9
497 hyperphosphatemia 9.9
498 vitamin b12 deficiency 9.9
499 metabolic acidosis 9.9
500 immunoglobulin alpha deficiency 9.9
501 pollen allergy 9.9
502 bone disease 9.9
503 thyroid gland anaplastic carcinoma 9.9
504 pemphigus foliaceus 9.9
505 dry eye syndrome 9.9
506 tonsillitis 9.9
507 esophageal atresia 9.9
508 osteomalacia 9.9
509 t cell deficiency 9.9
510 cardiac tamponade 9.9
511 familial hyperlipidemia 9.9
512 gestational diabetes 9.9
513 telangiectasis 9.9
514 hypochondriasis 9.9
515 persistent fetal circulation syndrome 9.9
516 eclampsia 9.9
517 anterior uveitis 9.9
518 estrogen excess 9.9
519 gonadal dysgenesis 9.9
520 pemphigoid gestationis 9.9
521 papilledema 9.9
522 pituitary cancer 9.9
523 melanoma 9.9
524 hepatitis b 9.9
525 constipation 9.9
526 hyperpituitarism 9.9
527 hereditary spastic paraplegia 9.9
528 hemangioma 9.9
529 relapsing polychondritis 9.9
530 cystic teratoma 9.9
531 cerebellar disease 9.9
532 acute kidney failure 9.9
533 papillary adenocarcinoma 9.9
534 lipid metabolism disorder 9.9
535 tropical spastic paraparesis 9.9
536 ischemia 9.9
537 thymic carcinoma 9.9
538 histiocytosis 9.9
539 mammary paget's disease 9.9
540 breast disease 9.9
541 cellulitis 9.9
542 superior mesenteric artery syndrome 9.9
543 pyoderma 9.9
544 bartter disease 9.9
545 rapidly progressive glomerulonephritis 9.9
546 proliferative glomerulonephritis 9.9
547 immune-complex glomerulonephritis 9.9
548 benign struma ovarii 9.9
549 sleep disorder 9.9
550 prolactinoma 9.9
551 panic disorder 9.9
552 reactive arthritis 9.9
553 acquired immunodeficiency syndrome 9.9
554 diffuse idiopathic skeletal hyperostosis 9.9
555 end stage renal disease 9.9
556 osteoarthritis 9.9
557 extrinsic allergic alveolitis 9.9
558 collagen disease 9.9
559 malignant hyperthermia 9.9
560 pyoderma gangrenosum 9.9
561 iridocyclitis 9.9
562 exposure keratitis 9.9
563 polyarteritis nodosa 9.9
564 hypertropia 9.9
565 drug reaction with eosinophilia and systemic symptoms 9.9
566 galactorrhoea-hyperprolactinaemia 9.9
567 pure autonomic failure 9.9
568 secondary adrenal insufficiency 9.9
569 spastic paraparesis 9.9
570 true thymic hyperplasia 9.9
571 paresthesia 9.9
572 autoimmune polyendocrinopathy type 3 9.9
573 acute sensory ataxic neuropathy 9.9
574 argyria 9.9
575 mitochondrial disease 9.9
576 acute liver failure 9.9
577 autoimmune hemolytic anemia, warm type 9.9
578 cardiogenic shock 9.9
579 thyroid ectopia 9.9
580 thrombotic microangiopathy 9.9
581 thyroid tumor 9.9
582 adrenal hyperplasia, congenital, due to 21-hydroxylase deficiency 9.9
583 alstrom syndrome 9.9
584 arachnoid cysts, intracranial 9.9
585 retinohepatoendocrinologic syndrome 9.9
586 cholangitis, primary sclerosing 9.9
587 periventricular nodular heterotopia 9.9
588 diffuse large b-cell lymphoma 9.9
589 amnestic disorder 9.9
590 dissociative disorder 9.9
591 visual epilepsy 9.9
592 sclerosing cholangitis 9.9
593 kikuchi disease 9.9
594 nonsyndromic hearing loss 9.9
595 nmda receptor encephalitis 9.9
596 maturity-onset diabetes of the young, type 1 9.9
597 eosinophilic fasciitis 9.9
598 wilson disease 9.9
599 budd-chiari syndrome 9.9
600 purpura fulminans 9.9
601 familial periodic paralysis 9.9
602 wernicke encephalopathy 9.9
603 thrombophilia 9.9
604 pulmonary fibrosis 9.9
605 nutritional deficiency disease 9.9
606 paraplegia 9.9
607 fatty liver disease 9.9
608 lymphosarcoma 9.9
609 pigmentation anomaly of the skin 9.9
610 3-methylglutaconic aciduria, type iii 9.9
611 osteogenic sarcoma 9.9
612 aspergillosis 9.9
613 left bundle branch hemiblock 9.9
614 allergic bronchopulmonary aspergillosis 9.9
615 myelitis 9.9
616 peptic ulcer disease 9.9
617 hemorrhoid 9.9
618 alzheimer disease, familial, 1 9.8
619 carcinoid tumors, intestinal 9.8
620 craniosynostosis 1 9.8
621 creutzfeldt-jakob disease 9.8
622 immunoglobulin a deficiency 1 9.8
623 macroglossia 9.8
624 goodpasture syndrome 9.8
625 pseudoxanthoma elasticum 9.8
626 macular degeneration, age-related, 1 9.8
627 riboflavin deficiency 9.8
628 autoimmune vasculitis 9.8
629 collagenous colitis 9.8
630 microinvasive gastric cancer 9.8
631 microcephaly 9.8
632 beriberi 9.8
633 familial hypercholesterolemia 9.8
634 sick sinus syndrome 9.8
635 adult-onset still's disease 9.8
636 polyclonal hypergammaglobulinemia 9.8
637 melancholia 9.8
638 churg-strauss syndrome 9.8
639 lipomatosis 9.8
640 syphilis 9.8
641 coronary stenosis 9.8
642 intracranial embolism 9.8
643 pituitary gland disease 9.8
644 aortic valve insufficiency 9.8
645 pellagra 9.8
646 amyloidosis 9.8
647 priapism 9.8
648 fasciitis 9.8
649 acute posterior multifocal placoid pigment epitheliopathy 9.8
650 heparin-induced thrombocytopenia 9.8
651 spondylarthropathy 9.8
652 systemic onset juvenile idiopathic arthritis 9.8
653 cerebral atrophy 9.8
654 hydrocephalus with stenosis of the aqueduct of sylvius 9.8
655 progressive muscular dystrophy 9.8
656 invasive mole 9.8
657 halo nevi 9.8
658 hydrocephalus, congenital, 1 9.8
659 congenital lipomatous overgrowth, vascular malformations, and epidermal nevi 9.8
660 drug allergy 9.8
661 pfeiffer syndrome 9.7
662 acromegaloid changes, cutis verticis gyrata, and corneal leukoma 9.7
663 alcohol dependence 9.7
664 angelman syndrome 9.7
665 annular erythema 9.7
666 episodic ataxia, type 2 9.7
667 bladder cancer 9.7
668 progressive familial heart block, type ia 9.7
669 breast cancer 9.7
670 cleft palate, isolated 9.7
671 coloboma of macula 9.7
672 papillorenal syndrome 9.7
673 creatine phosphokinase, elevated serum 9.7
674 cryoglobulinemia, familial mixed 9.7
675 diabetes insipidus, neurohypophyseal 9.7
676 ehlers-danlos syndrome, arthrochalasia type, 1 9.7
677 photoparoxysmal response 1 9.7
678 fibrosis of extraocular muscles, congenital, 1 9.7
679 lymphoma, mucosa-associated lymphoid type 9.7
680 gilbert syndrome 9.7
681 hypercholesterolemia, familial, 1 9.7
682 hypertension, essential 9.7
683 hypertriglyceridemia 1 9.7
684 chromosome 18p deletion syndrome 9.7
685 inclusion body myositis 9.7
686 kabuki syndrome 1 9.7
687 lacrimal duct defect 9.7
688 lentigines 9.7
689 leopard syndrome 1 9.7
690 leukemia, chronic lymphocytic 9.7
691 marfan syndrome 9.7
692 motion sickness 9.7
693 obsessive-compulsive disorder 9.7
694 benign chronic pemphigus 9.7
695 pemphigus vulgaris, familial 9.7
696 multiple endocrine neoplasia, type iia 9.7
697 alkaline phosphatase, plasma level of, quantitative trait locus 1 9.7
698 prader-willi syndrome 9.7
699 contractures, pterygia, and spondylocarpotarsal fusion syndrome 1a 9.7
700 raynaud disease 9.7
701 retinal detachment 9.7
702 schizophrenia 9.7
703 telangiectasia, hereditary benign 9.7
704 thyroglossal duct cyst, familial 9.7
705 williams-beuren syndrome 9.7
706 acth deficiency, isolated 9.7
707 adrenocortical carcinoma, hereditary 9.7
708 alopecia universalis congenita 9.7
709 amelogenesis imperfecta, hypomaturation type, iia1 9.7
710 takayasu arteritis 9.7
711 charge syndrome 9.7
712 pituitary adenoma 4, acth-secreting 9.7
713 deafness, onychodystrophy, osteodystrophy, mental retardation, and seizures syndrome 9.7
714 trichohepatoenteric syndrome 1 9.7
715 friedreich ataxia 9.7
716 galactorrhea 9.7
717 gastroschisis 9.7
718 hydatidiform mole, recurrent, 1 9.7
719 hemochromatosis, neonatal 9.7
720 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 9.7
721 hydrops fetalis, nonimmune 9.7
722 t-cell immunodeficiency with thymic aplasia 9.7
723 isovaleric acidemia 9.7
724 epilepsy, myoclonic juvenile 9.7
725 leigh syndrome 9.7
726 nonarteritic anterior ischemic optic neuropathy 9.7
727 thrombotic thrombocytopenic purpura, hereditary 9.7
728 thymoma, familial 9.7
729 pendred syndrome 9.7
730 mayer-rokitansky-kuster-hauser syndrome 9.7
731 toe syndactyly, telecanthus, and anogenital and renal malformations 9.7
732 wiskott-aldrich syndrome 9.7
733 hemophilia a 9.7
734 taqi polymorphism 9.7
735 type 1 diabetes mellitus 4 9.7
736 type 1 diabetes mellitus 8 9.7
737 fanconi anemia, complementation group e 9.7
738 suppression of tumorigenicity 12 9.7
739 type 1 diabetes mellitus 13 9.7
740 chromosome 18q deletion syndrome 9.7
741 type 1 diabetes mellitus 6 9.7
742 type 1 diabetes mellitus 10 9.7
743 myotonic dystrophy 2 9.7
744 huntington disease-like 1 9.7
745 sickle cell anemia 9.7
746 aceruloplasminemia 9.7
747 progressive familial heart block, type ib 9.7
748 huntington disease-like 3 9.7
749 lymphoma, non-hodgkin, familial 9.7
750 systemic lupus erythematosus 2 9.7
751 abdominal obesity-metabolic syndrome 1 9.7
752 aneurysmal bone cysts 9.7
753 maturity-onset diabetes of the young 9.7
754 huntington disease-like 2 9.7
755 polysubstance abuse 9.7
756 body mass index quantitative trait locus 1 9.7
757 glaucoma, normal tension 9.7
758 nasopharyngeal carcinoma 9.7
759 meningioma, familial 9.7
760 resting heart rate, variation in 9.7
761 thyroid carcinoma, hurthle cell 9.7
762 psoriatic arthritis 9.7
763 spastic paraplegia, ataxia, and mental retardation 9.7
764 tubulointerstitial nephritis with uveitis 9.7
765 neutrophilic dermatosis, acute febrile 9.7
766 endometrial cancer 9.7
767 leukemia, chronic myeloid 9.7
768 major depressive disorder 9.7
769 severe cutaneous adverse reaction 9.7
770 granulomatosis with polyangiitis 9.7
771 choanal atresia, posterior 9.7
772 autoimmune disease 4 9.7
773 preterm premature rupture of the membranes 9.7
774 mitral valve prolapse 3 9.7
775 intraocular pressure quantitative trait locus 9.7
776 acute promyelocytic leukemia 9.7
777 leukemia, acute lymphoblastic 9.7
778 fatty liver disease, nonalcoholic 1 9.7
779 alpha-1-antitrypsin deficiency 9.7
780 gastric cancer 9.7
781 hyperuricemia, pulmonary hypertension, renal failure, and alkalosis syndrome 9.7
782 beta-thalassemia 9.7
783 peripartum cardiomyopathy 9.7
784 intrauterine growth retardation, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomalies 9.7
785 short stature, onychodysplasia, facial dysmorphism, and hypotrichosis 9.7
786 facial dysmorphism, immunodeficiency, livedo, and short stature 9.7
787 immunodeficiency 19 9.7
788 vasculitis, autoinflammation, immunodeficiency, and hematologic defects syndrome 9.7
789 carbonic anhydrase va deficiency, hyperammonemia due to 9.7
790 hyperthyroxinemia, familial dysalbuminemic 9.7
791 cerebellofaciodental syndrome 9.7
792 spastic paraplegia, intellectual disability, nystagmus, and obesity 9.7
793 juvenile arthritis 9.7
794 restless legs syndrome 9.7
795 brugada syndrome 9.7
796 adult t-cell leukemia/lymphoma 9.7
797 familial atrial fibrillation 9.7
798 mantle cell lymphoma 9.7
799 paraganglioma 9.7
800 primary progressive multiple sclerosis 9.7
801 first-degree atrioventricular block 9.7
802 second-degree atrioventricular block 9.7
803 infective endocarditis 9.7
804 lymphoma 9.7
805 congenital ptosis 9.7
806 omphalocele 9.7
807 left ventricular noncompaction 9.7
808 salmonellosis 9.7
809 waldenstroem's macroglobulinemia 9.7
810 stickler syndrome 9.7
811 myoglobinuria 9.7
812 lymphoblastic lymphoma 9.7
813 cryptococcal meningitis 9.7
814 non-alcoholic fatty liver disease 9.7
815 non-alcoholic steatohepatitis 9.7
816 benign teratoma 9.7
817 familial glucocorticoid deficiency 9.7
818 autoimmune cholangitis 9.7
819 human cytomegalovirus infection 9.7
820 parkinsonism 9.7
821 nonobstructive coronary artery disease 9.7
822 acquired angioedema 9.7
823 progressive familial heart block 9.7
824 castleman disease 9.7
825 isolated elevated serum creatine phosphokinase levels 9.7
826 spermatogenic failure 9.7
827 sensorineural hearing loss 9.7
828 intracranial abscess 9.7
829 thalassemia 9.7
830 pleurisy 9.7
831 mumps 9.7
832 parotitis 9.7
833 endocarditis 9.7
834 lactose intolerance 9.7
835 chronic pyelonephritis 9.7
836 frontal sinusitis 9.7
837 malignant hypertension 9.7
838 fourth cranial nerve palsy 9.7
839 ovarian disease 9.7
840 qualitative platelet defect 9.7
841 pertussis 9.7
842 orbital cellulitis 9.7
843 disseminated intravascular coagulation 9.7
844 vitamin k deficiency bleeding 9.7
845 hantavirus hemorrhagic fever with renal syndrome 9.7
846 schizophreniform disorder 9.7
847 cerebral arteritis 9.7
848 adult respiratory distress syndrome 9.7
849 pyelonephritis 9.7
850 horner's syndrome 9.7
851 coronary thrombosis 9.7
852 ecthyma 9.7
853 panuveitis 9.7
854 dysthymic disorder 9.7
855 tinea corporis 9.7
856 superficial keratitis 9.7
857 oligohydramnios 9.7
858 paranoid schizophrenia 9.7
859 marasmus 9.7
860 alcoholic hepatitis 9.7
861 entropion 9.7
862 leukemia 9.7
863 conjugate gaze palsy 9.7
864 bell's palsy 9.7
865 retinal ischemia 9.7
866 respiratory syncytial virus infectious disease 9.7
867 ocular motility disease 9.7
868 miller fisher syndrome 9.7
869 carotid stenosis 9.7
870 dementia 9.7
871 focal segmental glomerulosclerosis 9.7
872 gout 9.7
873 substernal goiter 9.7
874 right bundle branch block 9.7
875 reading disorder 9.7
876 excessive tearing 9.7
877 toxic shock syndrome 9.7
878 childhood type dermatomyositis 9.7
879 renal tubular acidosis 9.7
880 noonan syndrome with multiple lentigines 9.7
881 46,xy sex reversal 9.7
882 46 xx gonadal dysgenesis 9.7
883 hereditary angioedema 9.7
884 panniculitis 9.7
885 arthus reaction 9.7
886 hypersensitivity reaction type iii disease 9.7
887 limited scleroderma 9.7
888 diffuse scleroderma 9.7
889 endogenous depression 9.7
890 heart septal defect 9.7
891 endocrine gland cancer 9.7
892 factitious disorder 9.7
893 status epilepticus 9.7
894 childhood absence epilepsy 9.7
895 hyperuricemia 9.7
896 thymus lipoma 9.7
897 blood platelet disease 9.7
898 granulomatous hepatitis 9.7
899 lateral sclerosis 9.7
900 protein s deficiency 9.7
901 central nervous system origin vertigo 9.7
902 larynx cancer 9.7
903 laryngeal benign neoplasm 9.7
904 epidermolysis bullosa 9.7
905 chorioangioma 9.7
906 long qt syndrome 9.7
907 euthyroid sick syndrome 9.7
908 cryoglobulinemia 9.7
909 membranoproliferative glomerulonephritis 9.7
910 early myoclonic encephalopathy 9.7
911 interstitial lung disease 9.7
912 mucinoses 9.7
913 demyelinating disease 9.7
914 tracheal stenosis 9.7
915 rhabdomyosarcoma 9.7
916 chronic granulomatous disease 9.7
917 thymus cancer 9.7
918 mixed type thymoma 9.7
919 temporal lobe epilepsy 9.7
920 inappropriate adh syndrome 9.7
921 plague 9.7
922 neurofibrosarcoma 9.7
923 gestational trophoblastic neoplasm 9.7
924 empty sella syndrome 9.7
925 lactic acidosis 9.7
926 granuloma annulare 9.7
927 arthropathy 9.7
928 hidrocystoma 9.7
929 pituitary-dependent cushing's disease 9.7
930 carcinosarcoma 9.7
931 polyradiculoneuropathy 9.7
932 epidermolysis bullosa acquisita 9.7
933 neuromuscular junction disease 9.7
934 subacute bacterial endocarditis 9.7
935 cervical adenitis 9.7
936 suppurative lymphadenitis 9.7
937 uremia 9.7
938 mesangial proliferative glomerulonephritis 9.7
939 ovarian cystic teratoma 9.7
940 ovarian cyst 9.7
941 chronic inflammatory demyelinating polyradiculoneuropathy 9.7
942 infertility 9.7
943 central nervous system vasculitis 9.7
944 internuclear ophthalmoplegia 9.7
945 prolactin producing pituitary tumor 9.7
946 peripheral nervous system disease 9.7
947 silent myocardial infarction 9.7
948 malignant peripheral nerve sheath tumor 9.7
949 ectopic thymus 9.7
950 central pontine myelinolysis 9.7
951 cowden syndrome 9.7
952 inherited metabolic disorder 9.7
953 bone epithelioid hemangioma 9.7
954 bilateral breast cancer 9.7
955 b-cell lymphoma 9.7
956 muscular atrophy 9.7
957 carotid artery occlusion 9.7
958 appendicitis 9.7
959 polycythemia 9.7
960 localized scleroderma 9.7
961 polyhydramnios 9.7
962 lung disease 9.7
963 reticulosarcoma 9.7
964 eating disorder 9.7
965 vascular dementia 9.7
966 erythema infectiosum 9.7
967 intermediate coronary syndrome 9.7
968 dermatophytosis 9.7
969 atrophic gastritis 9.7
970 macroglobulinemia 9.7
971 acute myocardial infarction 9.7
972 intracranial hypertension 9.7
973 meningitis 9.7
974 sheehan syndrome 9.7
975 dacryoadenitis 9.7
976 encephalitis 9.7
977 systolic heart failure 9.7
978 muscular dystrophy 9.7
979 orbit lymphoma 9.7
980 hypereosinophilic syndrome 9.7
981 bap1 tumor predisposition syndrome 9.7
982 familial paroxysmal nonkinesigenic dyskinesia 9.7
983 isolated gonadotropin-releasing hormone deficiency 9.7
984 pax2-related disorder 9.7
985 46, xy disorders of sexual development 9.7
986 acquired hemophilia 9.7
987 acquired hemophilia a 9.7
988 adrenomyeloneuropathy 9.7
989 alopecia totalis 9.7
990 aplasia cutis congenita 9.7
991 autoimmune atrophic gastritis 9.7
992 autoimmune encephalitis 9.7
993 broken heart syndrome 9.7
994 chromosomal triplication 9.7
995 congenital cytomegalovirus 9.7
996 cryofibrinogenemia 9.7
997 cutis verticis gyrata 9.7
998 diabetic mastopathy 9.7
999 diffuse mesangial sclerosis 9.7
1000 distal renal tubular acidosis 9.7
1001 hemophilia 9.7
1002 hypoaldosteronism 9.7
1003 laryngocele 9.7
1004 lymphocytic hypophysitis 9.7
1005 orbital lymphoma 9.7
1006 organic mood syndrome 9.7
1007 oto-palatal-digital syndrome 9.7
1008 ovarian epithelial cancer 9.7
1009 precocious puberty 9.7
1010 proximal chromosome 18q deletion syndrome 9.7
1011 retroperitoneal fibrosis 9.7
1012 ring chromosome 5 9.7
1013 sudden arrhythmia death syndrome 9.7
1014 superior limbic keratoconjunctivitis 9.7
1015 syndrome of inappropriate antidiuretic hormone 9.7
1016 warm antibody hemolytic anemia 9.7
1017 aldosterone-producing adenoma 9.7
1018 cerebral aneurysms 9.7
1019 headache 9.7
1020 hypertonia 9.7
1021 myoclonus 9.7
1022 myotonia 9.7
1023 posttransplant acute limbic encephalitis 9.7
1024 b-cell non-hodgkin lymphoma 9.7
1025 rare hyperthyroidism 9.7
1026 neonatal hypoxic and ischemic brain injury 9.7
1027 inherited cancer-predisposing syndrome 9.7
1028 fourth branchial cleft anomaly 9.7
1029 muscular lipidosis 9.7
1030 hemorrhagic fever-renal syndrome 9.7
1031 infundibulo-neurohypophysitis 9.7
1032 postpartum psychosis 9.7
1033 rare hyperkinetic movement disorder 9.7
1034 non-histaminic angioedema 9.7
1035 igg4-related thyroid disease 9.7
1036 seronegative autoimmune hepatitis 9.7
1037 autoimmune hepatitis type 2 9.7
1038 autoimmune hypoparathyroidism 9.7
1039 discoid lupus erythematosus 9.7
1040 x-linked intellectual disability-macrocephaly-macroorchidism syndrome 9.7
1041 rare tumor 9.7
1042 primary hypophysitis 9.7
1043 glomerular disease 9.7
1044 euthyroid dysprealbuminemic hyperthyroxinemia 9.7
1045 immune-mediated thrombotic thrombocytopenic purpura 9.7
1046 twin-reversed arterial perfusion sequence 9.7
1047 postinfectious cerebellitis 9.7

Graphical network of the top 20 diseases related to Graves' Disease:



Diseases related to Graves' Disease

Symptoms & Phenotypes for Graves' Disease

MGI Mouse Phenotypes related to Graves' Disease:

45 (showing 5, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.13 CD40 CTLA4 DIO2 GNAS HLA-DQA1 ICAM1
2 immune system MP:0005387 9.97 CD40 CTLA4 GNAS HLA-DQA1 ICAM1 IFNG
3 digestive/alimentary MP:0005381 9.86 CTLA4 DIO2 ICAM1 IFNG IL2RA IL4
4 skeleton MP:0005390 9.65 CD40 CTLA4 DIO2 GNAS IFNG IL2RA
5 hematopoietic system MP:0005397 9.47 CD40 CEP43 CTLA4 GNAS HLA-DQA1 ICAM1

Drugs & Therapeutics for Graves' Disease

Drugs for Graves' Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 104, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methimazole Approved Phase 4 60-56-0 1349907
2
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
3
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
4
Prednisolone Approved, Vet_approved Phase 4 50-24-8 4894 5755
5
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5 1875
6
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 4159 6741
7
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
8
Propranolol Approved, Investigational Phase 4 318-98-9, 525-66-6 62882 4946
9
Diclofenac Approved, Vet_approved Phase 4 15307-86-5, 15307-79-6 3033
10
Parathyroid hormone Approved, Investigational Phase 4 9002-64-6
11
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3 3680
12
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 3003 5743
13
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7 4897
14 Antithyroid Agents Phase 4
15
Methylprednisolone Acetate Phase 4 584547
16 Antirheumatic Agents Phase 4
17 BB 1101 Phase 4
18 Liver Extracts Phase 4
19 Adrenergic beta-1 Receptor Antagonists Phase 4
20 Adrenergic Antagonists Phase 4
21 Adrenergic Agents Phase 4
22 Antihypertensive Agents Phase 4
23 Cyclooxygenase Inhibitors Phase 4
24 Sympatholytics Phase 4
25 Anti-Inflammatory Agents, Non-Steroidal Phase 4
26 Analgesics, Non-Narcotic Phase 4
27 Analgesics Phase 4
28 Vasodilator Agents Phase 4
29 Anti-Arrhythmia Agents Phase 4
30 Neurotransmitter Agents Phase 4
31 Adrenergic beta-Antagonists Phase 4
32 Antibodies Phase 4
33 Immunoglobulins Phase 4
34 Pharmaceutical Solutions Phase 4
35 Lugol's solution Phase 4
36 Hormones Phase 4
37 Hormone Antagonists Phase 4
38 glucocorticoids Phase 4
39 Gastrointestinal Agents Phase 4
40 Antineoplastic Agents, Hormonal Phase 4
41 Antiemetics Phase 4
42 Anti-Inflammatory Agents Phase 4
43
Bupivacaine Approved, Investigational Phase 2, Phase 3 2180-92-9, 38396-39-3 2474
44
Carbimazole Approved, Investigational Phase 3 22232-54-8 31072
45
Racepinephrine Approved, Vet_approved Phase 2, Phase 3 51-43-4, 329-65-7 838 5816
46
Propylthiouracil Approved, Investigational Phase 3 51-52-5 657298
47 Anesthetics, Local Phase 2, Phase 3
48 Anesthetics Phase 2, Phase 3
49 Epinephryl borate Phase 2, Phase 3
50 Antimetabolites Phase 3
51
Insulin Phase 3
52 Insulin, Globin Zinc Phase 3
53 Hemostatics Phase 3
54 Coagulants Phase 3
55
Rituximab Approved Phase 1, Phase 2 174722-31-7
56
Oxytetracycline Approved, Investigational, Vet_approved Phase 1, Phase 2 79-57-2 54715139 54675779
57
Doxycycline Approved, Investigational, Vet_approved Phase 2 564-25-0 54671203
58
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
59
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030
60
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
61
Cholecalciferol Approved, Nutraceutical, Vet_approved Phase 2 67-97-0, 1406-16-2 5280795 10883523
62
Alfacalcidol Approved, Nutraceutical Phase 2 41294-56-8 5282181
63 Calciferol Phase 2
64 Vitamins Phase 2
65 Hydroxycholecalciferols Phase 2
66 Dihydroxycholecalciferols Phase 2
67 Antineoplastic Agents, Immunological Phase 1, Phase 2
68 Vaccines Phase 1, Phase 2
69 Antibodies, Monoclonal Phase 1, Phase 2
70 Antimalarials Phase 2
71 Antiprotozoal Agents Phase 2
72 Antiparasitic Agents Phase 2
73 Immunologic Factors Phase 2
74 Anti-Infective Agents Phase 2
75 Antifungal Agents Phase 2
76 Immunosuppressive Agents Phase 2
77 Antibiotics, Antitubercular Phase 2
78 Anti-Bacterial Agents Phase 2
79
Vitamin A Approved, Nutraceutical, Vet_approved Phase 1 2052-63-3, 22737-97-9, 22737-96-8, 68-26-8 9904001 9947823 5280382 445354
80 Retinol palmitate Phase 1
81
Xylometazoline Approved, Investigational 526-36-3 5709
82
Ganciclovir Approved, Investigational 82410-32-0 3454
83
Guaifenesin Approved, Investigational, Vet_approved 93-14-1 3516
84
Cathine Approved, Experimental, Illicit, Vet_approved, Withdrawn 14838-15-4, 492-39-7 131954576 4786 26934
85
Silicon Approved, Investigational 7440-21-3 4082203
86
Iodine Approved, Investigational 7553-56-2 807
87
Selenium Approved, Investigational, Vet_approved 7783-07-5, 7782-49-2 533
88
Bisphenol A Experimental 80-05-7 6623
89
Cadexomer iodine Experimental 94820-09-4
90 Mitogens
91 Neuroprotective Agents
92 Calcium, Dietary
93 Ganciclovir triphosphate
94 Factor VIII
95 Lipid Regulating Agents
96 Anticholesteremic Agents
97 Cholestyramine Resin
98 Hypolipidemic Agents
99 Chlorpheniramine, phenylpropanolamine drug combination
100 Micronutrients
101 Trace Elements
102 Protective Agents
103 Antioxidants
104
Calcium Nutraceutical 7440-70-2 271

Interventional clinical trials:

(showing 90, show less)
# Name Status NCT ID Phase Drugs
1 Impact of SSKI Pre-Treatment on Blood Loss in Thyroidectomy for Graves Disease Completed NCT00946296 Phase 4 Potassium Iodide
2 Prevention Relapse of Graves' Disease by Treatment With Intrathyroid Injection of Dexamethasone Completed NCT00917241 Phase 4 MMI combined with IID;MMI
3 Adjuvant Treatment of Graves´ Ophthalmopathy With NSAID (aGO Study) Completed NCT01458600 Phase 4 Diclofenac;Methimazole;L-thyroxin;Propranolol;Metoprolol
4 Influence of Methylprednisolone Pulse Therapy on Liver Function in Patients With Graves' Orbitopathy Completed NCT03667157 Phase 4 every week IVMP therapy;very high doses IVMP therapy
5 The Influence of Continuous Treatment With Antithyroid Drugs on the Effect of Radioiodine in Patients With Hyperthyroidism Completed NCT00150137 Phase 4 Methimazole
6 The Influence of Continuous Block-replacement Therapy on the Effect of Radioiodine in Patients With Hyperthyroidism Completed NCT00150124 Phase 4 MTZ+LT4;Methimazole
7 Diagnostic Accuracy Study of Indocyanine Green for Parathyroid Perfusion Assessment Completed NCT03969108 Phase 4 Indocyanine Green
8 Is the Routine Pressure Dressing After Thyroidectomy Necessary? A Prospective Randomized Controlled Study Completed NCT00400465 Phase 4
9 Clinical Study on the Effect of Routine Treatment and Intensive Treatment on the Regulation of Graves' Disease and the Cumulative Recurrence Two Years After Drug Withdrawal Recruiting NCT05461820 Phase 4 Methimazole
10 Randomized Clinical Trial, Blinded for the Researcher and Multicenter, to Evaluate the Efficacy and Safety of Preoperative Preparation With Lugol Solution in Euthyroid Patients With Graves-Basedow Disease. Recruiting NCT03980132 Phase 4 Lugols Strong Iodine
11 Randomized Controlled Trial of Preoperative Corticosteroids in Autoimmune ThyroidDisease Not yet recruiting NCT05435547 Phase 4 Dexamethasone;Placebo
12 Prospective Randomized Clinical Trial of Total Thyroidectomy (Tx) Versus Thionamides (Anti-Thyroid Drugs) in Patients With Moderate-to-Severe Graves' Ophthalmopathy - a 1-year Follow-up Unknown status NCT03066076 Phase 3 Antithyroid Drug
13 A Multi-center, Open Label, Randomised Parallel- Group Study to Compare the Efficacy of Cholestyramine Plus Standard Treatment Versus Prednisolone Plus Standard Treatment Versus Standard Treatment Alone in Treatment of Overt Hyperthyroidism Unknown status NCT03303053 Phase 3 Cholestyramine Powder 4g;Prednisolone;Standard treatment
14 Bupivacaine Injection of Eye Muscles to Treat Strabismus Unknown status NCT01616108 Phase 2, Phase 3 Bupivacaine
15 Effect of Hyperthyroidism and Its Treatment in Graves' Disease to Early Marker of Atherosclerosis: Review on the Pathway of Insulin Resistance, Lipid, Inflammation, and Endothelial Dysfunction to Pulse Wave Velocity and Carotid Intima-Media Thickness Completed NCT05118542 Phase 3 Propylthiouracil;Methimazole
16 Prevention of Overt Hypothyroidism Following Radioactive Iodine Therapy for Graves' Disease Completed NCT01950260 Phase 2, Phase 3 Levothyroxine
17 Comparison of Different Doses of 131I in Severe Graves' Hyperthyroidism: A Clinical Trial With Historical Control Completed NCT01039818 Phase 3
18 Assessing the Impact of the Early and Systematic Hormonal Replacement After Radio-isotopic Ablation of Graves'hyperthyroïdism on Quality of Life, Efficiency and Tolerance Completed NCT01295333 Phase 3 the early prophylactic introduction of low dose of LT4 (50 µg/d) at 15 days post-ablation;The initiation of LT4 as soon as the first biological signs of hypothyroidism.
19 Does the Use of Pre-operative SSKI Actually Reduce Vascularity and Improve Surgical Outcomes for Total Thyroidectomy in Graves' Disease? Recruiting NCT04080505 Phase 3 SSKI- Potassium Iodide
20 Preoperative Lugol's Solution in Graves' Disease and Toxic Nodular Goiter Recruiting NCT04856488 Phase 3 Iodine-Potassium Iodide 5%-10% Oral and Topical Solution
21 A Phase III, Randomized, Controlled, Open Label, no Profit, Single-center Intervention Study to Compare the Effect of a Conservative (Antithyroid Drugs) and an Ablative Approach (Radioiodine or Total Thyroidectomy) for the Treatment of Hyperthyroidism in Patients With Graves' Disease and Moderate-to-severe and Active Graves' Orbitopathy (GO) Treated With Intravenous Glucocorticoids (ABLAGO Study) Not yet recruiting NCT04776993 Phase 3 Methimazole
22 Investigation of Novel Biomarkers and Definition of the Role of the Microbiome In Graves' Orbitopathy Unknown status NCT02373995 Phase 1, Phase 2
23 Radioactive Iodide Therapy for Pediatric Graves' Disease Completed NCT01269749 Phase 2 ATD Group
24 Effects Of Oral Alfacalcidol On Maturation Of Dendritic Cells In Graves' Disease Patients Completed NCT02993302 Phase 2 1α-D3;Placebos
25 B Cell Depletion With the Anti-CD20 Monoclonal Antibody Rituximab in the Treatment of Graves' Disease Completed NCT00150111 Phase 1, Phase 2 Methimazole;Rituximab
26 An Open Label Study to Evaluate the Safety and Efficacy of 12 Week Treatment With CFZ533 in Patients With Graves' Disease Completed NCT02713256 Phase 2 CFZ533
27 Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy: a Prospective, Uncontrolled Pilot Study Completed NCT01727973 Phase 1, Phase 2 Doxycycline
28 Pretreatment With Recombinant Human Thyrotropin (rhTSH) for the Effect on Thyroid Size and Function, and for the Effect of Radioiodine Treatment in Patients With Nodular Goiter. Prospective, Randomized Double-blinded Trials. Completed NCT00145366 Phase 2 Recombinant human thyrotropin (Thyrogen)
29 The Effect of Subantimicrobial Dose Doxycycline in Mild Thyroid-Associated Ophthalmopathy Recruiting NCT02203682 Phase 2 Doxycycline hyclate;Placebo
30 A Phase II, Randomized, Superiority, Adaptive, Open-label, Single-center, Clinical Trial to Evaluate the Efficacy of Sirolimus (Rapamycin) in Patients With Graves' Disease and Moderate-to-severe and Active Graves' Orbitopathy (GO) Not yet recruiting NCT04598815 Phase 2 Sirolimus
31 K1-70 - A Phase I, Single Ascending Intramuscular Dose or Single Ascending Intravenous Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Subjects With Graves' Disease Completed NCT02904330 Phase 1 K1-70 intramuscular or K1-70 intravenous
32 Safety and Proof of Principle Study of ATX-GD-59 in Male and Female Subjects With Graves' Disease Not Currently Treated With Anti-thyroid Therapy: An Open Label Study, With an Upward Titration Over Five Dose Levels Administered by Intradermal Injection Completed NCT02973802 Phase 1
33 Function of Regulatory T Cells Improved by Treatment With an Intrathyroid Injection of Dexamethasone in Graves' Patients Completed NCT01534169 Phase 1 Dexamethasone
34 Bio-psycho-social Correlates of Psychological Distress in Patients With Graves' Disease in Euthyroid Status Unknown status NCT02620085
35 Prevalence of Graves Disease in Patients With Ulcerative Colitis Unknown status NCT03324334
36 Total Versus Subtotal Thyroidectomy in Graves' Disease : A Randomized Controlled Trial Unknown status NCT04577664
37 The Effect of Different Calculated Doses of I-131 in Treatment of Patients With Grave's Disease Unknown status NCT02114619 Low dose of I-131;Intermediate dose;High dose
38 Application of Digital Infrared Thermal Imaging in Thyroid Disease and Associated Ophthalmopathy and Dermopathy Unknown status NCT01182584
39 Comparison of Standardized Update Value Using Single-photo Emission Computed Tomography and Computed Tomography Between Grave's Disease (Hyperthyroidism) Patients and Normal Humans Unknown status NCT02772705
40 Shared Decision Making in Graves Disease - Graves Disease (GD) Choice Completed NCT02107794
41 A Randomized, Open-label, Parallel-group Study to Explore the Efficacy of High-intensity Focused Ultrasound (HIFU) Versus Fixed-dose Radioiodine-131 in the Treatment of Relapsed Graves' Disease Completed NCT03013257
42 Five-year Follow up of a Randomized Clinical Trial of Bilateral Subtotal Thyroidectomy Versus Total Thyroidectomy for Graves' Disease. Completed NCT01408368
43 Serum Antibodies Against the Insulin-like Growth Factor-1 Receptor (IGF-1R) in Graves' Disease and Graves' Orbitopathy Completed NCT03498417
44 A Prospective Evaluation of High Intensity Focused Ultrasound (HIFU) in the Treatment of Relapsed Graves' Disease Completed NCT02685514
45 Prospective Randomized Study of Therapy Withdrawal vs Continued Low Dose Medical Therapy in Patients With Graves' Disease Entering Remission During ATD Therapy Completed NCT00796913
46 A Prospective Study Analyzing the Change of Gut Microbiome With Antithyroid Drug Treatment of Graves' Disease Completed NCT04383795 Antithyroid Drug
47 Study of the Influence of the GST, CYP and TP53 Gene Polymorphisms in the Risk of Graves' Disease and Its Outcome. Completed NCT00505011
48 Positive Effect of Lugol's Solution on the Blood Flow and Microvessel Density of Thyroid Gland in the Patients With Graves' Disease Completed NCT00432146 lugol's solution
49 Prevalence of Circulating Parvovirus Genome in Recently Diagnosed Graves' Disease: a Case-control Study Completed NCT02798965
50 Differential Diagnosis Value of Peak Systolic Velocity of Thyroid Superior Artery Using Color Flow Doppler Sonography in Transient Thyrotoxicosis Caused by Thyroiditis and Graves Disease Completed NCT01227499
51 TSH Receptor Antibody Heterogeneity in Children and Adolescents With Graves' Disease Completed NCT00335062
52 Use of Low-dose Radioiodine for Ablation of Thyroid Remnants in Patients With Graves' Disease Following Thyroidectomy Completed NCT03110835
53 An Observational, Retrospective, Single-center, Clinical Study to Evaluate the Efficacy of Sirolimus (Rapamycin) in Patients With Graves' Disease and Moderate-to-severe and Active Graves' Orbitopathy (GO) Completed NCT05345119 Sirolimus;Methylprednisolone
54 The DAGMAR Study. D-vitamin And Graves' Disease; Morbidity And Relapse Reduction: A Randomised, Clinical Trial. Completed NCT02384668
55 Characteristics of Islet β-cell Functions in Chinese Patients With Graves' Disease Completed NCT02376088 Methimazole
56 Increased Heart Rhythm in Response to High-dose Intravenous Methylprednisolone Pulse Therapy of Moderate-to-severe Graves' Orbitopathy Completed NCT04391439 Intravenous Methylprednisolone
57 Effectiveness of Classical Potassium Iodide Therapy for the Treatment of Untreated Patients With Graves' Hyperthyroidism, Avoiding Thionamide Drugs With Serious Side Effects of Agranulocytosis, Liver Injury, Vasculitis, Embryopathy or Frequent Side Effects of Skin Eruption Completed NCT04686006 Potassium Iodide
58 Evaluation of Optimal Time of Methimazole Discontinuation Before Radio-iodine Therapy in Hyperthyroid Grave's Patients Completed NCT01560299 Methimazole
59 Proof-of-Principle Trial of Communication to Patients Receiving Predictive Genetic Risk Assessment Completed NCT00782366
60 Blood Pressure Profile and NT-proBNP Dynamics in Response to Intravenous Methylprednisolone Pulse Therapy of Severe Graves' Orbitopathy Completed NCT03590080 Methylprednisolone
61 Analysis of Bisphenol A Concentration in Serum in Women of Reproductive Age With Autoimmune Thyroid Disease Completed NCT04682340
62 High-dose Intravenous Methylprednisolone Therapy in Patients With Graves' Orbitopathy is Associated With the Increased Activity of Factor VIII Completed NCT03535090 Methylprednisolone
63 Clinical Application of Continuous Monitoring Data for the Pulse Rate, Exercise, and Calorie Intake by Wearable Activity Trackers in the Patients With Thyrotoxicosis Completed NCT03009357
64 Determining the Association Between Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity Completed NCT03941184
65 A Randomized Control Trial Comparing Bilateral Superficial Cervical Plexus Block and Local Wound Infiltration in Thyroidectomy and Parathyroidectomy Completed NCT02205801 0.9% saline;Marcaine
66 Color Doppler Imaging of Orbital Venous Flow in Grave's Orbitopathy Completed NCT00697528
67 Phase II Randomized Controlled Study of Sequential Orbital Radiotherapy for Graves' Ophthalmopathy Completed NCT00004660
68 Randomized Open Clinical Study to Evaluate the Efficacy of Selenium Plus Methimazole for Treatment of Graves' Hyperthyroidism Completed NCT02727738 Methimazole
69 Thyroid Disorders in Malaysian: A Nationwide Multicentre Study Completed NCT02190214
70 Low Doses of Cholestyramine in the Treatment of Hyperthyroidism Completed NCT00677469 Cholestyramine;Placebo powder
71 Autoimmune Thyroid Disease Genetic Study Completed NCT00958113
72 POST-RADIOIODINE GRAVES' MANAGEMENT Completed NCT01885533
73 Study of DNA Methylation in Children and Adolescents With Autoimmune Thyroid Diseases Completed NCT02491567
74 Arathyroid Reimplantation in Forearm Subcutaneous Tissue During Thyroidectomy: a Simple Way to Avoid Ipoparathyroidism and Evaluate Graft Function Completed NCT02194920
75 A Prospective Randomized Equivalence Trial to Evaluate the Safety of the Ligasure in Thyroid Surgery Completed NCT01163565
76 A Randomized, Open-label, Parallel-group Study to Determine the Efficacy of Sequential High-intensity Focused Ultrasound (HIFU) Ablation Versus Fixed-dose Radioiodine-131 Therapy in Moderate-sized Non-toxic Multinodular Goiter Completed NCT04009863
77 The Observation Study of Graves' Disease Cohort Recruiting NCT05043233 Methimazole(MMI)
78 Clinical Usefulness of Monitoring Heart Rate Using Wearable Devices in the Patients of Graves' Disease Who Discontinue Anti-thyroid Drugs Recruiting NCT04333342
79 Resting Heart Rate Monitoring for Optimized Treatment and Surveillance of Hyperthyroidism Recruiting NCT04932135
80 Personalized Treatment Planning for Radio-iodine Therapy of Thyroid Disease Recruiting NCT03517579
81 Three-dimensional Ultrasonography: Accuracy in Thyroid Volume Measurement. Recruiting NCT05510609
82 Evaluation of Patients With Thyroid Function Disorders Recruiting NCT00001159
83 Mechanism of NK Cell Disfunction in Graves' Disease Active, not recruiting NCT04135573
84 The Epidemiology, Management, and the Associated Burden of Mental Health, Atopic and Autoimmune Conditions, and Common Infections in Alopecia Areata Active, not recruiting NCT04239521
85 The Epidemiology, Management and Associated Conditions in Alopecia Areata in Czech Republic: A University-clinic-based Retrospective Cohort Study Active, not recruiting NCT05098600
86 An Assessment of the Occurrence of Hypothyroidism in Patients Treated With RAI For Hyperthyroidism, And it's Prognostic Factors. Active, not recruiting NCT04663451
87 GRAves Selenium Supplementation Trial (GRASS) - an Investigator-initiated Randomised, Blinded, Multicentre Clinical Trial of Selenium Supplementation Versus Placebo in Patients With Graves' Hyperthyroidism Active, not recruiting NCT01611896
88 Additional Autoimmune Diseases With Type 1 Diabetes in Children and Adolescents at Diabetes Diagnostic and During Follow-up : a Monocentric Study in France Enrolling by invitation NCT04789993
89 Next-generation Sequencing (NGS) of Peripheral Blood Immune Repertoire in Graves' Disease Not yet recruiting NCT02210741
90 Randomized Trial Comparing Complication Rates Associated With Robot-assisted Thyroidectomy to External Thyroidectomy Terminated NCT01320813

Search NIH Clinical Center for Graves' Disease

Cochrane evidence based reviews: graves disease

Genetic Tests for Graves' Disease

Genetic tests related to Graves' Disease:

# Genetic test Affiliating Genes
1 Graves Disease 28

Anatomical Context for Graves' Disease

Organs/tissues related to Graves' Disease:

FMA: Thyroid Gland
MalaCards : Thyroid, Eye, Skin, Heart, Bone, Brain, T Cells

Publications for Graves' Disease

Articles related to Graves' Disease:

(showing 14898, show less)
# Title Authors PMID Year
1
Gene polymorphisms of interleukin-4, interleukin-10 and transforming growth factor-beta in Graves' disease. 53 62
19882211 2010
2
HLA and CTLA4 polymorphisms may confer a synergistic risk in the susceptibility to Graves' disease. 53 62
20300120 2010
3
Immunopathogenesis of thyroid eye disease: emerging paradigms. 53 62
20385333 2010
4
Four patients with hypothyroid Graves' disease. 53 62
20421660 2010
5
Pathogenesis of thyroid eye disease--does autoimmunity against the TSH receptor explain all cases? 53 62
20464711 2010
6
Association of the CTLA4 gene with Graves' disease in the Chinese Han population. 53 62
20352109 2010
7
Clinical associations of the genetic variants of CTLA-4, Tg, TSHR, PTPN22, PTPN12 and FCRL3 in patients with Graves' disease. 53 62
19438904 2010
8
Resistance to thyroid hormone in a patient with coexisting Graves' disease. 53 62
20151830 2010
9
The level of TSH appeared favourable in maintaining bone mineral density in postmenopausal women. 53 62
20151763 2010
10
A long-term follow-up of serum myeloperoxidase antineutrophil cytoplasmic antibodies (MPO-ANCA) in patients with Graves disease treated with propylthiouracil. 53 62
19851036 2010
11
TSH receptor autoantibodies. 53 62
19332151 2009
12
Type 1 diabetes and autoimmune polyglandular syndrome: a clinical review. 53 62
20009114 2009
13
[New assays of TSH-receptor antibodies: analytical and clinical performances in the diagnosis of Graves' disease]. 53 62
19939769 2009
14
Thyroid peroxidase forms thionamide-sensitive homodimers: relevance for immunomodulation of thyroid autoimmunity. 53 62
19669106 2009
15
49A/G and CT60 polymorphisms of the cytotoxic T-lymphocyte-associated antigen 4 gene associated with autoimmune thyroid disease. 53 62
19559744 2009
16
Association of polymorphism at position 49 in exon 1 of the cytotoxic T-lymphocyte-associated factor 4 gene with Graves' disease refractory to medical treatment, but not with amiodarone-associated thyroid dysfunction. 53 62
19731979 2009
17
Autoimmune thyroid disease: unlocking a complex puzzle. 53 62
19474733 2009
18
Type 2 deiodinase Thr92Ala polymorphism impact on clinical course and myocardial remodeling in patients with Graves' disease. 53 62
19684474 2009
19
Association of CTLA-4 gene polymorphism with Graves' disease and ophthalmopathy in Iranian patients. 53 62
19524188 2009
20
Vitamin D receptor (VDR) gene polymorphisms and Graves' disease: a meta-analysis. 53 62
18782354 2009
21
The T393C polymorphism of the Galphas gene (GNAS1) is associated with the course of Graves' disease. 53 62
19513951 2009
22
The relationship between thyroid function, serum monokine induced by interferon gamma and soluble interleukin-2 receptor in thyroid autoimmune diseases. 53 62
19250272 2009
23
Monokine induced by interferon gamma (IFNgamma) (CXCL9) and IFNgamma inducible T-cell alpha-chemoattractant (CXCL11) involvement in Graves' disease and ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. 53 62
19276231 2009
24
Cytotoxic T lymphocyte-associated molecule-4 polymorphism in Turkish patients with Hashimoto thyroiditis. 53 62
19284444 2009
25
[Thyroid-stimulating hormone receptor antibodies in the diagnosis of Graves' disease in children]. 53 62
19388481 2009
26
Polymorphisms in the ADRB2 gene and Graves disease: a case-control study and a meta-analysis of available evidence. 53 62
19284637 2009
27
Membranous nephropathy associated with thyroid-peroxidase antigen. 53 62
18762990 2009
28
Graves' disease occurring after surgery of a multinodular goiter: a case report. 53 62
18563680 2009
29
Pendrin is a novel autoantigen recognized by patients with autoimmune thyroid diseases. 53 62
19050049 2009
30
An investigation of the C77G and C772T variations within the human protein tyrosine phosphatase receptor type C gene for association with multiple sclerosis in an Australian population. 53 62
19111528 2009
31
Association of the IL2RA/CD25 gene with juvenile idiopathic arthritis. 53 62
19116909 2009
32
First automated assay for thyrotropin receptor autoantibodies. 53 62
19634982 2009
33
Association of CD40 and thyroglobulin genes with later-onset Graves' disease in Taiwanese patients. 53 62
18755875 2008
34
No association between Fas A/G polymorphism and therapeutic effects induced by methimazole treatment for Graves' disease in Northern Chinese. 53 62
18972838 2008
35
Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves' disease. 53 62
18768899 2008
36
CTLA4 gene polymorphisms in children and adolescents with autoimmune thyroid diseases. 53 62
18752454 2008
37
Association of CT60 polymorphism of the CTLA4 gene with Graves' disease in Taiwanese children. 53 62
18780601 2008
38
Association of CTLA-4 and IL-13 gene polymorphisms with Graves' disease and ophthalmopathy in Chinese children. 53 62
18296657 2008
39
Associations of protein tyrosine phosphatase nonreceptor 22 (PTPN22) gene polymorphisms with susceptibility to Graves' disease in a Japanese population. 53 62
18578611 2008
40
Differential expression of Fas system apoptotic molecules in peripheral lymphocytes from patients with Graves' disease and Hashimoto's thyroiditis. 53 62
18505906 2008
41
Association of the interleukin (IL)-16 gene polymorphisms with Graves' disease. 53 62
18394967 2008
42
Thyrotoxicosis factitia masquerading as recurrent Graves' disease: endogenous antibody immunoassay interference, a pitfall for the unwary. 53 62
18482926 2008
43
PTPRC (CD45) variation and disease association studied using single nucleotide polymorphism tagging. 53 62
18312479 2008
44
Thyroglobulin mRNA expression in peripheral blood lymphocytes of healthy subjects and patients with thyroid disease. 53 62
18243140 2008
45
An alternative therapy for graves' disease: clinical effects and mechanisms of an herbal remedy. 53 62
18379045 2008
46
Enhancement of experimental Graves' disease by intranasal administration of a T cell epitope of the thyrotropin receptor. 53 62
18234558 2008
47
The functional R620W variant of the PTPN22 gene is associated with celiac disease. 53 62
18194365 2008
48
Multiple sclerosis and the CTLA4 autoimmunity polymorphism CT60: no association in patients from Germany, Hungary and Poland. 53 62
17942509 2008
49
Polymorphism of the oestrogen receptor beta gene (ESR2) is associated with susceptibility to Graves' disease. 53 62
17941906 2008
50
Family-based association study of cytotoxic T-lymphocyte antigen-4 with susceptibility to Graves' disease in Han population of Taiwan. 53 62
18059468 2008
51
The common variants of E-selectin gene in Graves' disease. 53 62
18094708 2008
52
Exon 33 T/T genotype of the thyroglobulin gene is a susceptibility gene for Graves' disease in Taiwanese and exon 12 C/C genotype protects against it. 53 62
18385936 2008
53
Characterization of thyroglobulin epitopes in patients with autoimmune and non-autoimmune thyroid diseases using recombinant human monoclonal thyroglobulin autoantibodies. 53 62
18029466 2008
54
Thyroglobulin polymorphisms in Tunisian patients with autoimmune thyroid diseases (AITD). 53 62
18656705 2008
55
Association analysis of vitamin D receptor gene polymorphisms with bone mineral density in young women with Graves' disease. 53 62
18506225 2008
56
On specificity of 2nd generation TSH receptor autoantibody measurements. 53 62
18942492 2008
57
Graves' disease in Brazilian children and adults: lack of genetic association with CTLA-4 +49A>G polymorphism. 53 62
18493148 2008
58
Are porcine and human TSH receptor antibody measurements comparable? 53 62
18510037 2008
59
The link between Graves' disease and Hashimoto's thyroiditis: a role for regulatory T cells. 53 62
17823263 2007
60
Structure, inhibitor, and regulatory mechanism of Lyp, a lymphoid-specific tyrosine phosphatase implicated in autoimmune diseases. 53 62
18056643 2007
61
Prognostic value of thyrotropin receptor antibodies (TRAb) in Graves' disease: a 120 months prospective study. 53 62
17675761 2007
62
Susceptible alleles of the CD40 and CTLA-4 genes are not associated with the relapse after antithyroid withdrawal in Graves' disease. 53 62
17949264 2007
63
New HLA DRB1 and DQB1 haplotypes in a pedigree of familial Graves' disease in Japan. 53 62
17785916 2007
64
Preliminary evidence for interaction of PTPN12 polymorphism with TSHR genotype and association with Graves' ophthalmopathy. 53 62
17608818 2007
65
[Age related changes of soluble Fas, Fas ligand and Bcl-2 in autoimmune thyroid diseases]. 53 62
18205105 2007
66
The thyrotropin receptor in Graves' disease. 53 62
17822379 2007
67
Methimazole inhibits CXC chemokine ligand 10 secretion in human thyrocytes. 53 62
17911406 2007
68
Protein tyrosine phosphatase PTPN22 in human autoimmunity. 53 62
17729039 2007
69
Role of chemokines in endocrine autoimmune diseases. 53 62
17475924 2007
70
Cytotoxic T-lymphocyte associated antigen 4 gene polymorphisms and autoimmune thyroid disease: a meta-analysis. 53 62
17504905 2007
71
[Analysis of Fas, FasL and Caspase-8 expression in thyroid gland in young patients with immune and non-immune thyroid diseases]. 53 62
18058722 2007
72
The calcium-sensing receptor is a target of autoantibodies in patients with autoimmune polyendocrine syndrome type 1. 53 62
17374709 2007
73
Sources of circulating 3,5,3'-triiodothyronine in hyperthyroidism estimated after blocking of type 1 and type 2 iodothyronine deiodinases. 53 62
17389703 2007
74
The adaptation and relationship of FGF-23 to changes in mineral metabolism in Graves' disease. 53 62
17437520 2007
75
Polymorphisms of interleukin (IL)-4 receptor alpha and signal transducer and activator of transcription-6 (Stat6) are associated with increased IL-4Ralpha-Stat6 signalling in lymphocytes and elevated serum IgE in patients with Graves' disease. 53 62
17362266 2007
76
Changes in expression of T-helper (Th) 1- and Th2-associated chemokine receptors on peripheral blood lymphocytes and plasma concentrations of their ligands, interferon-inducible protein-10 and thymus and activation-regulated chemokine, after antithyroid drug administration in hyperthyroid patients with Graves' disease. 53 62
17535861 2007
77
Soluble CTLA-4 in autoimmune thyroid diseases: relationship with clinical status and possible role in the immune response dysregulation. 53 62
17321799 2007
78
The diagnostic criteria of Graves' disease and especially the thyrotropin receptor antibody; our own experience. 53 62
17684583 2007
79
Association of the interleukin-2 receptor alpha (IL-2Ralpha)/CD25 gene region with Graves' disease using a multilocus test and tag SNPs. 53 62
17371467 2007
80
Intercellular adhesion molecule 1 gene polymorphisms do not contribute to Graves' disease in Chinese patients. 53 62
17873320 2007
81
Aberrant expression of the insulin-like growth factor-1 receptor by T cells from patients with Graves' disease may carry functional consequences for disease pathogenesis. 53 62
17312178 2007
82
Mapping of human autoantibody epitopes on aromatic L-amino acid decarboxylase. 53 62
17200166 2007
83
Production of interleukin (IL)-5 and IL-10 accompanies T helper cell type 1 (Th1) cytokine responses to a major thyroid self-antigen, thyroglobulin, in health and autoimmune thyroid disease. 53 62
17223970 2007
84
Induction of stimulating thyrotropin receptor antibodies after radioiodine therapy for toxic multinodular goitre and Graves' disease measured with a novel bioassay. 53 62
17198353 2007
85
Cytokine promoter polymorphisms in Taiwanese patients with Graves' disease. 53 62
17208210 2007
86
Association between vitamin-D receptor gene FokI polymorphism and Graves' disease among Taiwanese Chinese. 53 62
17506475 2007
87
beta-2-adrenergic receptor gene polymorphism confers susceptibility to Graves disease. 53 62
17143563 2007
88
Anti-thyroid-stimulating hormone receptor antibodies determined by second-generation assay. 53 62
17243910 2007
89
Serum CD40/CD40L system in Graves' disease and Hashimoto's thyroiditis related to soluble Fas, FasL and humoral markers of autoimmune response. 53 62
17558708 2007
90
Effect of methimazole treatment for 2 years on circulating IL-4, IgE, TBII, and TSAb in patients with hyperthyroid Graves' disease. 53 62
16983180 2006
91
Effects of TSH receptor mutations on binding and biological activity of monoclonal antibodies and TSH. 53 62
17199429 2006
92
Association of TNF-alpha, TNF-beta, IFN-gamma and IL-1Ra gene polymorphisms with Graves' disease in the Thai population. 53 62
17348243 2006
93
The predictive value of CTLA-4 and Tg polymorphisms in the recurrence of Graves' disease after antithyroid withdrawal. 53 62
17526951 2006
94
Association of Graves' disease and Graves' ophthalmopathy with the polymorphisms in promoter and exon 1 of cytotoxic T lymphocyte associated antigen-4 gene. 53 62
17048303 2006
95
Evidence for unique association signals in SLE at the CD28-CTLA4-ICOS locus in a family-based study. 53 62
17000707 2006
96
A differential association of interferon-gamma high-producing allele T and low-producing allele A (+874 A/T) with Hashimoto's thyroiditis and Graves' disease. 53 62
16970687 2006
97
Differential evolution of thyroid peroxidase and thyrotropin receptor antibodies in Graves' disease: thyroid peroxidase antibody activity reverts to pretreatment level after carbimazole withdrawal. 53 62
17042691 2006
98
Use of Tag single nucleotide polymorphisms (SNPs) to screen PTPN21: no association with Graves' disease. 53 62
16918960 2006
99
Detection of thyroid peroxidase mRNA and protein in orbital tissue. 53 62
16868133 2006
100
Protein tyrosine phosphatase non-receptor type 22 (PTPN22) gene R620W variant and sporadic idiopathic hypoparathyroidism in Asian Indians. 53 62
16893384 2006
101
Expression of TPO and ThOXs in human thyrocytes is downregulated by IL-1alpha/IFN-gamma, an effect partially mediated by nitric oxide. 53 62
16478776 2006
102
The common -318C/T polymorphism in the promoter region of CTLA4 gene is associated with reduced risk of ophthalmopathy in Chinese Graves' patients. 53 62
16893393 2006
103
CTLA4 polymorphisms and ophthalmopathy in Graves' disease patients: association study and meta-analysis. 53 62
16916658 2006
104
Interleukin-4 induces 15-lipoxygenase-1 expression in human orbital fibroblasts from patients with Graves disease. Evidence for anatomic site-selective actions of Th2 cytokines. 53 62
16675443 2006
105
Thyrotropin receptor epitopes and their relation to histocompatibility leukocyte antigen-DR molecules in Graves' disease. 53 62
16595602 2006
106
Vitamin D-binding protein (DBP) gene polymorphism is associated with Graves' disease and the vitamin D status in a Polish population study. 53 62
16868893 2006
107
Status of anti-thyroid peroxidase during normal pregnancy and in patients with hyperemesis gravidarum. 53 62
16756470 2006
108
Immunoglobulin G from patients with Graves' disease induces interleukin-16 and RANTES expression in cultured human thyrocytes: a putative mechanism for T-cell infiltration of the thyroid in autoimmune disease. 53 62
16410300 2006
109
Possible interaction between HLA-DRbeta1 and thyroglobulin variants in Graves' disease. 53 62
16646680 2006
110
Lack of a genetic association between the CTLA-4 gene and Graves' disease in Koreans. 53 62
16571085 2006
111
[Serum IL-1 receptor antagonist and IL-1beta in patients with Graves' opthalmopathy]. 53 62
16608084 2006
112
Self-reactive CD4+ T cells and B cells in the blood in health and autoimmune disease: increased frequency of thyroglobulin-reactive cells in Graves' disease. 53 62
16602033 2006
113
Incidence of postradioiodine immunogenic hyperthyroidism/Graves' disease in relation to a temporary increase in thyrotropin receptor antibodies after radioiodine therapy for autonomous thyroid disease. 53 62
16571091 2006
114
Genetic analysis and functional evaluation of the C/T(-318) and A/G(-1661) polymorphisms of the CTLA-4 gene in patients affected with Graves' disease. 53 62
16297665 2006
115
Association between the TAP2 gene codon 665 polymorphism and Graves' disease. 53 62
16721835 2006
116
[Role of apoptosis in autoimmune thyroid disorders]. 53 62
17020659 2006
117
Soluble Fas, Fas ligand and Bcl-2 in autoimmune thyroid diseases: relation to humoral immune response markers. 53 62
17357290 2006
118
Application of mouse monoclonal antibodies for identification of antigen regions of human thyroid peroxidase in adolescents with Graves' disease and non-toxic multinodular goiter by flow cytometry. 53 62
16390813 2005
119
Polymorphisms at +49A/G and CT60 sites in the 3' UTR of the CTLA-4 gene and APECED-related AIRE gene mutations analysis in sporadic idiopathic hypoparathyroidism. 53 62
16313305 2005
120
Analysis of costimulatory molecules OX40/4-1BB (CD134/CD137) detection on chosen mononuclear cells in children and adolescents with Graves' disease during methimazole therapy. 53 62
16459462 2005
121
IL-13 and chromosome 5q31-q33: problems of identifying association within regions of linkage to Graves' disease. 53 62
16343107 2005
122
A sparse marker extension tree algorithm for selecting the best set of haplotype tagging single nucleotide polymorphisms. 53 62
16294299 2005
123
Haplotype tagging efficiency in worldwide populations in CTLA4 gene. 53 62
16034471 2005
124
Association of CD40 gene polymorphism (C-1T) with susceptibility and phenotype of Graves' disease. 53 62
16279844 2005
125
Vitamin D receptor polymorphisms are associated with Graves' disease in German and Polish but not in Serbian patients. 53 62
16279845 2005
126
Lack of mutations in the TSHr and Gsalpha genes in TSHr antibody negative Graves' disease. 53 62
16235153 2005
127
Insight into Graves' hyperthyroidism from animal models. 53 62
15827111 2005
128
[A woman complicated with immune thrombocytopenic purpura, subclinical Graves disease and peripheral neuropathy 5 years after allogeneic bone marrow transplantation]. 53 62
16440775 2005
129
[Hypokalemic thyrotoxic periodic paralysis (HTPP). Rare differential diagnosis in case of acute tetraparesis in Europe]. 53 62
16170648 2005
130
CYP27B1 gene polymorphism is associated with Graves' disease in a Polish population study. 53 62
16187925 2005
131
Cytotoxic T lymphocyte-associated molecule-4 polymorphisms in Turkish Graves' disease patients and association with probability of remission after antithyroid therapy. 53 62
16137550 2005
132
A C/T polymorphism in the 5' untranslated region of the CD40 gene is associated with later onset of Graves' disease in Japanese. 53 62
16127217 2005
133
Association of vitamin D receptor gene polymorphism with susceptibility to Graves' disease in Eastern Croatian population: case-control study. 53 62
16100768 2005
134
Determination of the levels of anti-thyroid-stimulating hormone receptor antibody with thyroid peroxidase antibody in Omani patients with Graves' disease. 53 62
15961927 2005
135
Thyrotropin receptor autoantibodies in Graves' disease. 53 62
15950483 2005
136
Expression of pendrin in benign and malignant human thyroid tissues. 53 62
15942636 2005
137
Fibroblast growth factor-23 in patients with Graves' disease before and after antithyroid therapy: its important role in serum phosphate regulation. 53 62
15827108 2005
138
A haplotype of the CYP27B1 promoter is associated with autoimmune Addison's disease but not with Graves' disease in a UK population. 53 62
15956353 2005
139
Quantification of cells expressing the thyrotropin receptor in extraocular muscles in thyroid associated orbitopathy. 53 62
15923509 2005
140
Association of HLA-DR and -DQ genes with Graves disease in Koreans. 53 62
15993720 2005
141
Epitope analysis of myeloperoxidase-specific antineutrophil cytoplasmic autoantibodies (MPO-ANCA) in childhood onset Graves' disease treated with propylthiouracil. 53 62
15960145 2005
142
Isolation and characterisation of a human monoclonal autoantibody to the islet cell autoantigen IA-2. 53 62
15869863 2005
143
Arg16Gly polymorphism in beta2-adrenergic receptor gene is not associated with thyrotoxic periodic paralysis in Korean male patients with Graves' disease. 53 62
15853829 2005
144
Elevated serum interferon-gamma-inducible chemokine-10/CXC chemokine ligand-10 in autoimmune primary adrenal insufficiency and in vitro expression in human adrenal cells primary cultures after stimulation with proinflammatory cytokines. 53 62
15657375 2005
145
Peroxiredoxin 5 expression in the human thyroid gland. 53 62
15785239 2005
146
CT60 single nucleotide polymorphisms of the cytotoxic T-lymphocyte-associated antigen-4 gene region is associated with Graves' disease in an Italian population. 53 62
15785242 2005
147
Interleukin-1-beta gene, but not the interleukin-1 receptor antagonist gene, is associated with Graves' disease. 53 62
16025481 2005
148
Relationship between CTLA-4 and CD28 molecule expression on T lymphocytes and stimulating and blocking autoantibodies to the TSH-receptor in children with Graves' disease. 53 62
16220002 2005
149
Association of HLA-DR, -DQ genotype and CTLA-4 gene polymorphism with Graves' disease in Japanese children. 53 62
15640608 2005
150
[Cytofluorymetric evaluation of antigen regions of human thyroid peroxidase in patients with Graves' disease and non-toxic multinodular goiter using mouse monoclonal antibodies]. 53 62
15850534 2005
151
Regression mapping of association between the human leukocyte antigen region and Graves disease. 53 62
15558498 2005
152
Association study between the IL4, IL13, IRF1 and UGRP1 genes in chromosomal 5q31 region and Chinese Graves' disease. 53 62
16195814 2005
153
CT60 single nucleotide polymorphism of the CTLA-4 gene is associated with susceptibility to Graves' disease in the Taiwanese population. 53 62
16081581 2005
154
[Relationship between OX40/4-1 BB (CD134/CD137) costimulatory molecules expression on T lymphocytes and stimulating and blocking autoantibodies to the TSH-receptor in children with Graves' disease]. 53 62
16232366 2005
155
The onset of Graves' disease during the clinical course of myeloperoxidase antineutrophil cytoplasmic antibody (MPO-ANCA)-associated glomerulonephritis. 53 62
17029081 2005
156
Lack of association between IL-12B gene polymorphism and autoimmune thyroid disease in Japanese patients. 53 62
15644581 2004
157
The codon 620 tryptophan allele of the lymphoid tyrosine phosphatase (LYP) gene is a major determinant of Graves' disease. 53 62
15531553 2004
158
Association between the TAP1 gene codon 637 polymorphism and Graves' disease. 53 62
15711027 2004
159
Immunoglobulins from patients with Graves' disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor. 53 62
15472208 2004
160
Intrathyroidal CD4+ T lymphocytes express high levels of Fas and CD4+ CD8+ macrophages/dendritic cells express Fas ligand in autoimmune thyroid disease. 53 62
15588377 2004
161
Thyroid papillary carcinoma: preliminary evidence for a germ-line single nucleotide polymorphism in the Fas gene. 53 62
15350189 2004
162
CTLA-4 (CD152) gene polymorphism at position 49 in exon 1 in Graves' disease in a Polish population of the Lower Silesian region. 53 62
15507878 2004
163
Synovial fibroblasts from patients with rheumatoid arthritis, like fibroblasts from Graves' disease, express high levels of IL-16 when treated with Igs against insulin-like growth factor-1 receptor. 53 62
15322222 2004
164
A promoter polymorphism of the CYP27B1 gene is associated with Addison's disease, Hashimoto's thyroiditis, Graves' disease and type 1 diabetes mellitus in Germans. 53 62
15296474 2004
165
Residues 34-39 in the thyrotropin receptor are not the target of autoantibodies from sera of patients with Graves' disease. 53 62
15554359 2004
166
Concentration-dependent regulation of thyrotropin receptor function by thyroid-stimulating antibody. 53 62
15173885 2004
167
Interleukin-4 stimulates papillary thyroid cancer cell survival: implications in patients with thyroid cancer and concomitant Graves' disease. 53 62
15181072 2004
168
Increased intensities of fas expression on peripheral T-cell subsets in severe autoimmune thyroid disease. 53 62
15242568 2004
169
CTLA-4 gene polymorphism and its association with Graves' disease in the Lebanese population. 53 62
15182328 2004
170
Analysis of the expression of Fas, FasL and Bcl-2 in the pathogenesis of autoimmune thyroid disorders. 53 62
16219172 2004
171
Lack of association of the vitamin D receptor gene with Graves' disease in UK Caucasians. 53 62
15104566 2004
172
Ultrastructural localization of thyroid peroxidase, hydrogen peroxide-generating sites, and monoamine oxidase in benign and malignant thyroid diseases. 53 62
15116324 2004
173
Evaluation of a coated-tube assay for antithyrotropin receptor antibodies in patients with Graves' disease and other thyroid disorders. 53 62
15142363 2004
174
Dynamics of thyroid-stimulating and -blocking antibodies to the thyrotropin receptor in a murine model of Graves' disease. 53 62
14764633 2004
175
Novel aspects of orbital fibroblast pathology. 53 62
15165000 2004
176
[Magnetic resonance imaging and soluble forms of adhesion molecules: sICAM and sVCAM in assessing the activity of thyroid orbitopathy]. 53 62
15230228 2004
177
[Assessment of soluble E selectin levels in patients with Graves' disease and thyroid orbitopathy]. 53 62
15850320 2004
178
Autoantibodies in autoimmune thyroid disease promote immune complex formation with self antigens and increase B cell and CD4+ T cell proliferation in response to self antigens. 53 62
14971052 2004
179
[Analysis of costimulatory molecules (CD28-CTLA-4/B7) expression on chosen mononuclear cells in adolescents with Graves' disease during methimazole therapy]. 53 62
15504312 2004
180
Low-dose immunization with adenovirus expressing the thyroid-stimulating hormone receptor A-subunit deviates the antibody response toward that of autoantibodies in human Graves' disease. 53 62
14576177 2004
181
Thyroid-stimulating hormone receptor and its role in Graves' disease. 53 62
14654350 2003
182
CTLA-4 AT-repeat polymorphism reduces the inhibitory function of CTLA-4 in Graves' disease. 53 62
14751028 2003
183
The effect of thyrotropin-receptor blocking antibodies on stimulating autoantibodies from patients with Graves' disease. 53 62
14751037 2003
184
Relapse of Graves' disease in a patient with pheochromocytoma. 53 62
14709850 2003
185
Preferential megalin-mediated transcytosis of low-hormonogenic thyroglobulin: a control mechanism for thyroid hormone release. 53 62
14657389 2003
186
Fine-tuning of T lymphocytes in autoimmunity: genetic association of CTLA-4 variants and Graves' disease revisited. 53 62
14616877 2003
187
No association of two Fas gene polymorphisms with Hashimoto's thyroiditis and Graves' disease. 53 62
14585083 2003
188
Interleukin-13 gene polymorphisms in patients with Graves' disease. 53 62
14510917 2003
189
Early changes in thyroid-stimulating antibody activity following radioiodine therapy. 53 62
12966202 2003
190
[Analysis of TNFbeta gene microsatellite polymorphism in Graves disease]. 53 62
15639929 2003
191
The putative role of fibroblasts in the pathogenesis of Graves' disease: evidence for the involvement of the insulin-like growth factor-1 receptor in fibroblast activation. 53 62
14669949 2003
192
Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens. 53 62
12965943 2003
193
Polymorphism in the transmembrane region of the major histocompatibility complex class I chain-related gene A: association of five GCT repetitions with Graves' disease in children. 53 62
14588097 2003
194
Modulation of dendritic cell function and cytokine production to prevent thyroid autoimmunity. 53 62
14669946 2003
195
Defective function of Fas in T cells from paediatric patients with autoimmune thyroid diseases. 53 62
12930371 2003
196
Detection and localization of chemokine gene expression in autoimmune thyroid disease. 53 62
12864798 2003
197
Exon-1 polymorphism of ctla-4 gene in Iranian patients with Graves' disease. 53 62
14567561 2003
198
CTLA4 gene and Graves' disease: association of Graves' disease with the CTLA4 exon 1 and intron 1 polymorphisms, but not with the promoter polymorphism. 53 62
12780750 2003
199
The thyrotropin receptor autoantigen in Graves disease is the culprit as well as the victim. 53 62
12813025 2003
200
Autoantibodies against glutamic acid decarboxylase and 21-hydroxylase in Brazilian patients with type 1 diabetes or autoimmune thyroid diseases. 53 62
14635733 2003
201
Evidence for intramolecular B-cell epitope spreading during experimental immunization with an immunogenic thyroglobulin peptide. 53 62
12780685 2003
202
HLA-G does not have a pathophysiological role in Graves' disease. 53 62
12783978 2003
203
Association of Graves' disease with intragenic polymorphism of the thyrotropin receptor gene in a cohort of Singapore patients of multi-ethnic origins. 53 62
12930595 2003
204
Etiopathogenesis of Graves' disease. 53 62
14523350 2003
205
Regulation of the phosphatidylinositol 3-kinase, Akt/protein kinase B, FRAP/mammalian target of rapamycin, and ribosomal S6 kinase 1 signaling pathways by thyroid-stimulating hormone (TSH) and stimulating type TSH receptor antibodies in the thyroid gland. 53 62
12668683 2003
206
Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves' disease is mediated through the insulin-like growth factor I receptor pathway. 53 62
12794168 2003
207
Induction of murine thyroiditis by a non dominant E(k)-restricted peptide of human thyroglobulin. 53 62
12667218 2003
208
A method for identification of the peptides that bind to a clone of thyroid-stimulating antibodies in the serum of Graves' disease patients. 53 62
12679441 2003
209
The association of HLA -A, -B, and -DRB1 genotypes with Graves' disease in Taiwanese people. 53 62
12694583 2003
210
Fas ligand gene polymorphisms are not associated with Hashimoto's thyroiditis and Graves' disease. 53 62
12559631 2003
211
Pax-8 expression correlates with type II 5' deiodinase expression in thyroids from patients with Graves' disease. 53 62
12699588 2003
212
Contrasting activities of thyrotropin receptor antibodies in experimental models of Graves' disease induced by injection of transfected fibroblasts or deoxyribonucleic acid vaccination. 53 62
12488353 2003
213
Differential expression of galectin-3 in papillary projections of malignant and non-malignant hyperplastic thyroid lesions. 53 62
15179758 2003
214
[Antibodies to glutamic acid decarboxylase in patients with Graves disease]. 53 62
15600194 2003
215
[Usefulness of soluble ICAM-1 measurements for the evaluation of the disease activity and efficiency of therapy in patients with infiltrative Graves' ophthalmopathy]. 53 62
12687928 2002
216
[A linkage study of cytotoxic T lymphocyte-associated antigen 4 gene and Graves' disease in northern Chinese Han ethnic]. 53 62
12654233 2002
217
Long-term pathologic changes of alpha1-acid glycoprotein (orosomucoid) glycoforms in autoimmune thyroid disease. 53 62
12685872 2002
218
Thyroglobulin mRNA quantification in the peripheral blood is not a reliable marker for the follow-up of patients with differentiated thyroid cancer. 53 62
12444888 2002
219
Expression of very late antigen-4 and lymphocyte function-associated antigen-1 on peripheral blood lymphocytes from patients with graves disease. 53 62
12357047 2002
220
A successful pregnancy and delivery case of Graves' disease with myeloperoxidase antineutrophil cytoplasmic antibody induced by propylthiouracil. 53 62
12507274 2002
221
[Basedow disease occurring after allogeneic bone marrow transplantation for acute lymphoblastic leukemia]. 53 62
12412287 2002
222
Distinctive response of thyroid-infiltrating mononuclear cells to B cell activation through CD40 and interleukin-4 in Graves' patients. 53 62
12242076 2002
223
[The influence of corticosteroids on IL-6/IL-6R system in patients with Graves' ophthalmopathy]. 53 62
12476893 2002
224
Demonstration of immunoglobulin G, A, and E autoantibodies to the human thyrotropin receptor using flow cytometry. 53 62
11932312 2002
225
A novel murine model of Graves' hyperthyroidism with intramuscular injection of adenovirus expressing the thyrotropin receptor. 53 62
11884447 2002
226
Different intrathyroid expression of intercellular adhesion molecule-1 (ICAM-1) in Hashimoto's thyroiditis and Graves' disease: analysis at mRNA level and association with B7.1 costimulatory molecule. 53 62
11936473 2002
227
Relation of three polymorphisms of the CTLA-4 gene in patients with Graves' disease. 53 62
11936461 2002
228
Allele frequency of two intragenic microsatellite loci of SEL1L gene in Northern Italian population. 53 62
12030374 2002
229
Graves' disease is associated with an altered CXCR3 and CCR5 expression in thyroid-derived compared to peripheral blood lymphocytes. 53 62
11966764 2002
230
CD45 exon 4 point mutation does not confer susceptibility to type 1 diabetes mellitus or Graves' disease. 53 62
11841494 2002
231
Demonstration of reduced in vivo surface expression of activating mutant thyrotrophin receptors in thyroid sections. 53 62
11834424 2002
232
Importance of the detection method for thyroglobulin antibodies for the validity of thyroglobulin measurements in sera from patients with Graves disease. 53 62
11751544 2002
233
CTLA-4 gene polymorphisms in Tunisian patients with Graves' disease. 53 62
11726229 2001
234
Thyroid peroxidase autoantibodies obtained from random single chain FV libraries contain the same heavy/light chain combinations as occur in vivo. 53 62
11606439 2001
235
Effects of prolactin on HLA-DR and CD40 expressions by human thyrocytes. 53 62
11729509 2001
236
Thyroid transcription factor-2 gene expression in benign and malignant thyroid lesions. 53 62
11762722 2001
237
Apoptosis induced by FasL and TRAIL/Apo2L in the pathogenesis of thyroid diseases. 53 62
11595539 2001
238
Expression of CD40 and apoptosis related molecules in autoimmune thyroid diseases. 53 62
11675676 2001
239
Serum L-selectin and ICAM-1 in patients with Graves' ophthalmopathy during treatment with corticosteroids. 53 62
11578685 2001
240
Is there loss or qualitative changes in the expression of thyroid peroxidase protein in thyroid epithelial cancer? 53 62
11556840 2001
241
Characterization of the secretable ectodomain of thyrotropin receptor produced by the recombinant baculovirus system. 53 62
11514051 2001
242
MHC class II region, CTLA4 gene, and ophthalmopathy in patients with Graves' disease. 53 62
11583755 2001
243
Bone mineral density in male patients with L-thyroxine suppressive therapy and Graves disease. 53 62
11683428 2001
244
B-cell autoepitopes on the acetylcholinesterase-homologous region of human thyroglobulin: association with Graves' disease and thyroid eye disease. 53 62
11454506 2001
245
Remission and recurrence of hyperthyroid Graves' disease during and after methimazole treatment when assessed by IgE and interleukin 13. 53 62
11502776 2001
246
Identification of the peptides that inhibit the function of human monoclonal thyroid-stimulating antibodies from phage-displayed peptide library. 53 62
11443206 2001
247
Reduced expression of stromal-derived factor 1 in autonomous thyroid adenomas and its regulation in thyroid-derived cells. 53 62
11443213 2001
248
Serum levels of cytokines in children and adolescents with Graves' disease and non-toxic nodular goiter. 53 62
11453524 2001
249
Fas/FasL mediated apoptosis of thyrocytes in Graves' disease. 53 62
11422195 2001
250
Extrathyroidal manifestations of Graves' disease: the thyrotropin receptor is expressed in extraocular, but not cardiac, muscle tissues. 53 62
11344244 2001
251
Expression of thyrotropin receptors in rat thymus. 53 62
11432444 2001
252
Frequency of appearance of myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA) in Graves' disease patients treated with propylthiouracil and the relationship between MPO-ANCA and clinical manifestations. 53 62
11380496 2001
253
Screening for an AIRE-1 mutation in patients with Addison's disease, type 1 diabetes, Graves' disease and Hashimoto's thyroiditis as well as in APECED syndrome. 53 62
11298085 2001
254
Nuclear localization of epidermal growth factor and epidermal growth factor receptors in human thyroid tissues. 53 62
11288982 2001
255
Alternatively spliced form of human thyroperoxidase, TPOzanelli: activity, intracellular trafficking, and role in hormonogenesis. 53 62
11327880 2001
256
[The role od adhesion molecules in the pathogenesis of Graves ophthalmopathy]. 53 62
11873415 2001
257
Pertinence of kappa and lambda recombinant antibodies directed against thyroid peroxidase in thyroid autoimmune disease. 53 62
11847422 2001
258
Vitamin D receptor gene polymorphism is associated with Graves' disease in the Japanese population. 53 62
11134121 2000
259
CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves' disease. 53 62
11086105 2000
260
Cytokines, IgG subclasses and costimulation in a mouse model of thyroid autoimmunity induced by injection of fibroblasts co-expressing MHC class II and thyroid autoantigens. 53 62
11091271 2000
261
Prevalence of thyroid peroxidase, thyroglobulin and thyrotropin receptor antibodies in a long-term follow-up of juvenile Graves disease. 53 62
11092696 2000
262
Thyroid-stimulating antibody is related to Graves' ophthalmopathy, but thyrotropin-binding inhibitor immunoglobulin is related to hyperthyroidism in patients with Graves' disease. 53 62
11041459 2000
263
Circulating thyroglobulin transcytosed by thyroid cells in complexed with secretory components of its endocytic receptor megalin. 53 62
10999849 2000
264
Genetic determinants of Graves disease. 53 62
11001797 2000
265
Development of serum-free bioreactor production of recombinant human thyroid stimulating hormone receptor. 53 62
11027160 2000
266
Changes in cytokine production during pregnancy in patients with Graves' disease. 53 62
11014316 2000
267
A new assay for thyroglobulin concentration in serum using monoclonal antibodies against synthetic peptides. 53 62
10876005 2000
268
Serum concentrations of proinflammatory cytokines in Graves' disease: effect of treatment, thyroid function, ophthalmopathy and cigarette smoking. 53 62
10913938 2000
269
An elevation of serum immunoglobulin E provides a new aspect of hyperthyroid Graves' disease. 53 62
10946880 2000
270
[Impact of serum thyroglobulin concentration in the diagnosis of benign and malignant thyroid diseases]. 53 62
10984889 2000
271
Death of the autoimmune thyrocyte: is it pushed or does it jump? 53 62
10958308 2000
272
The prevalence and clinical significance of blocking thyrotropin receptor antibodies in untreated hyperthyroid Graves' disease. 53 62
10958310 2000
273
Complex association analysis of graves disease using a set of polymorphic markers. 53 62
10924276 2000
274
Serum cytokines levels in Graves' disease. 53 62
11500727 2000
275
Fas ligand expression in thyroid follicular cells from patients with thionamide-treated Graves' disease. 53 62
10958304 2000
276
Serum levels of the cytokines IL-1beta, IL-6 and ICAM-1 after 131I-treatment of Graves' disease and nodular goiter. 53 62
10965935 2000
277
Anti-TSH receptor antibodies in clinical practice. 53 62
10874533 2000
278
Vitamin D receptor initiation codon polymorphism in Japanese patients with Graves' disease. 53 62
10907990 2000
279
Trends in diagnostic and therapeutic criteria in Graves' disease in the last 10 years. 53 62
10824047 2000
280
Concordance of eight kits for antithyroid peroxidase autoantibodies determination. 53 62
10987206 2000
281
Production of IL-10 and IL-12 in CD40 and interleukin 4-activated mononuclear cells from patients with Graves' disease. 53 62
10843746 2000
282
Vitamin D receptor initiation codon polymorphism in Japanese patients with Graves' disease. 53 62
10884183 2000
283
The human leukocyte antigen HLA DRB3*020/DQA1*0501 haplotype is associated with Graves' disease in African Americans. 53 62
10770195 2000
284
Human anti-thyroid peroxidase single-chain fragment variable of Ig isolated from a combinatorial library assembled in-cell: insights into the in vivo situation. 53 62
10754281 2000
285
Transcriptional regulation of the MHC II gene DRA in untransformed human thyrocytes. 53 62
10744641 2000
286
A heterozygous deletion of the autoimmune regulator (AIRE1) gene, autoimmune thyroid disease, and type 1 diabetes: no evidence for association. 53 62
10720083 2000
287
Pendrin, the protein encoded by the Pendred syndrome gene (PDS), is an apical porter of iodide in the thyroid and is regulated by thyroglobulin in FRTL-5 cells. 53 62
10650967 2000
288
Analysis of the genetic variability of the 1st (CCC/ACC, P52T) and the 10th exons (bp 1012-1704) of the TSH receptor gene in Graves' disease. 53 62
10651846 2000
289
Thyrocyte proliferation by cellular adhesion to infiltrating lymphocytes through the intercellular adhesion molecule-1/lymphocyte function-associated antigen-1 pathway in Graves' disease. 53 62
10634414 2000
290
A novel mouse model of Graves' disease: implications for a role of aberrant MHC class II expression in its pathogenesis. 53 62
11129118 2000
291
Serum cytokine levels in autoimmune and non-autoimmune hyperthyroid states. 53 62
10625876 2000
292
[Serum levels of adhesion molecules (sICAM-1, sVCAM-1 and sP-selectin) in children and adolescents with thyroid diseases]. 53 62
12818068 2000
293
Autoantibodies against aromatic L-amino acid decarboxylase identifies a subgroup of patients with Addison's disease. 53 62
10634424 2000
294
The quantitative measurement of autoantibodies to thyroglobulin and thyroid peroxidase by automated microparticle based immunoassays in Hashimoto's disease, Graves' disease and a follow-up study on postpartum thyroid disease. 53 62
10745983 2000
295
Peptides of human thyroglobulin reactive with sera of patients with autoimmune thyroid disease. 53 62
10570317 1999
296
Limitations of the semisynthetic library approach for obtaining human monoclonal autoantibodies to the thyrotropin receptor of Graves' disease. 53 62
10540180 1999
297
Increase in serum concentrations of thyroxine-binding globulin and of cortisol-binding globulin after the induction of normal thyroid function in previously hyperthyroid patients. 53 62
10595456 1999
298
Effect of radioactive iodine therapy on cytokine production in Graves' disease: transient increases in interleukin-4 (IL-4), IL-6, IL-10, and tumor necrosis factor-alpha, with longer term increases in interferon-gamma production. 53 62
10566657 1999
299
[Increased serum soluble Fas ligand in hyperthyroid Graves' disease]. 53 62
10590671 1999
300
Graves' immunoglobulins activate phospholipase A2 by recognizing specific epitopes on thyrotropin receptor. 53 62
10487700 1999
301
Germline polymorphism of codon 727 of human thyroid-stimulating hormone receptor is associated with toxic multinodular goiter. 53 62
10487707 1999
302
Special features of Graves' disease in early childhood. 53 62
10524565 1999
303
Antithyroid drugs inhibit radioiodine-induced increases in thyroid autoantibodies in hyperthyroid Graves' disease. 53 62
10482369 1999
304
Differences between changes in serum thyrotropin-binding inhibitory antibodies and thyroid-stimulating antibodies in the course of antithyroid drug therapy for Graves' disease. 53 62
10482368 1999
305
Functional Fas ligand expression in thyrocytes from patients with Graves' disease. 53 62
10443697 1999
306
[Apoptosis in the pathogenesis of autoimmune thyroid disease]. 53 62
10483239 1999
307
[An elevation of serum immunoglobulin E provides a new aspect of hyperthyroid Graves' disease]. 53 62
10483274 1999
308
[Serum thyroglobulin measurement and its clinical significance]. 53 62
10483254 1999
309
The development of Graves' disease and the CTLA-4 gene on chromosome 2q33. 53 62
10404810 1999
310
The cytotoxic T lymphocyte antigen-4 is a major Graves' disease locus. 53 62
10369864 1999
311
Epitope heterogeneity of thyrotropin receptor-blocking antibodies in Graves' patients as detected with wild-type versus chimeric thyrotropin receptors. 53 62
10411114 1999
312
Longitudinal study of soluble intercellular adhesion molecule-1 (ICAM-1) in sera of patients with Graves' disease. 53 62
10435852 1999
313
Direct binding of thyrotropin receptor autoantibody to in vitro translated thyrotropin receptor: a comparison to radioreceptor assay and thyroid stimulating bioassay. 53 62
10365678 1999
314
Identification of thyroid hormone residues on serum thyroglobulin: a clue to the source of circulating thyroglobulin in thyroid diseases. 53 62
10229914 1999
315
Increased serum soluble Fas in patients with Graves' disease. 53 62
10319938 1999
316
Two Graves' disease patients who spontaneously developed hypothyroidism after antithyroid drug treatment: characteristics of epitopes for thyrotropin receptor antibodies. 53 62
10319947 1999
317
Reactivity of anti-thyroid antibodies to thyroglobulin tryptic fragments: comparison of autoimmune and non-autoimmune thyroid diseases. 53 62
10347809 1999
318
CD30 expression and interleukin-4 and interferon-gamma production of intrathyroidal lymphocytes in Graves' disease. 53 62
10319937 1999
319
Regulation and transfer of a murine model of thyrotropin receptor antibody mediated Graves' disease. 53 62
10067867 1999
320
The A-G polymorphism in exon 1 of the CTLA-4 gene is not associated with systemic lupus erythematosus. 53 62
10364920 1999
321
Analysis of a microsatellite polymorphism of the cytotoxic T-lymphocyte antigen-4 gene in patients with vitiligo. 53 62
10215771 1999
322
The alterations of CD11A expression on peripheral blood lymphocytes/monocytes and CD62L expression on peripheral blood lymphocytes in Graves' disease and type 1 diabetes. 53 62
10697430 1999
323
Second generation assay for thyrotropin receptor antibodies has superior diagnostic sensitivity for Graves' disease. 53 62
9920067 1999
324
Limited usefulness of antithyroperoxidase and antithyroglobulin assays in Jamaicans with Graves' disease. 53 62
10690629 1999
325
Graves' disease: xenotransplantation model (athymic nude mice). 53 62
9930960 1999
326
Thyrotropin receptor antibodies in black South African patients with Graves' disease and their response to medical therapy. 53 62
9972678 1998
327
Normal serum concentrations of sex hormone binding-globulin in patients with hyperthyroidism due to subacute thyroiditis. 53 62
9920365 1998
328
A cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphism is associated with autoimmune Addison's disease in English patients. 53 62
10197076 1998
329
Expression of thyrotropin receptor on clonal osteoblast-like rat osteosarcoma cells. 53 62
9848724 1998
330
Autoantibodies to tyrosinase-related protein-1 detected in the sera of vitiligo patients using a quantitative radiobinding assay. 53 62
9892944 1998
331
B7.1 costimulatory molecule is expressed on thyroid follicular cells in Hashimoto's thyroiditis, but not in Graves' disease. 53 62
9814503 1998
332
Interferon-gamma gene microsatellite polymorphisms in patients with Graves' disease. 53 62
9848715 1998
333
Analyses of the molecular forms of serum thyroglobulin from patients with Graves' disease, subacute thyroiditis or differentiated thyroid cancer by velocity sedimentation on sucrose gradient and Western blot. 53 62
9849814 1998
334
The expression of the beta 1 integrin CD29 and the beta 2 integrin CD11b is decreased in peripheral blood lymphocytes from Graves' disease patients. 53 62
9758448 1998
335
Serological reactivity of recombinant 1D autoantigen and its expression in human thyroid and eye muscle tissue: a possible autoantigenic link in Graves' patients. 53 62
9709953 1998
336
Lack of HLA-G soluble isoforms in Graves-Basedow thyrocytes and complete cDNA sequence of the HLA-G*01012 allele. 53 62
9777333 1998
337
A study of the association between a polymorphism in the CTLA-4 gene and postpartum thyroiditis. 53 62
9828915 1998
338
TAP1 polymorphism identified in African-American Graves' disease patients. 53 62
9730088 1998
339
Characterization of the murine immune response to the murine TSH receptor ectodomain: induction of hypothyroidism and TSH receptor antibodies. 53 62
9697993 1998
340
Lack of association of Graves' disease with the A2 allele of the interleukin-1 receptor antagonist gene in a white European population. 53 62
9678537 1998
341
CTLA-4 promoter variants in patients with Graves' disease and Hashimoto's thyroiditis. 53 62
9672157 1998
342
Elevated CD69 expression on naive peripheral blood T-cells in hyperthyroid Graves' disease and autoimmune thyroiditis: discordant effect of methimazole on HLA-DR and CD69. 53 62
9614932 1998
343
The thyrotropin receptor in thyroid eye disease. 53 62
9623732 1998
344
Antigen processing and autoimmunity. Evaluation of mRNA abundance and function of HLA-linked genes. 53 62
9599304 1998
345
Thyrotropin receptor expression in Graves' orbital adipose/connective tissues: potential autoantigen in Graves' ophthalmopathy. 53 62
9506762 1998
346
Preserved activation of thyrotropin receptor antibody to stimulate thyroid function despite long-term treatment in euthyroid patients with Graves' disease. 53 62
9539302 1998
347
The prognostic value of thyrotropin receptor antibody measurement in the early stages of treatment of Graves' disease with antithyroid drugs. 53 62
9510119 1998
348
Anaplastic transformation of a papillary carcinoma of the thyroid in a patient with Graves' disease with varied activity of thyrotropin receptor antibodies. 53 62
9492154 1998
349
Association of CTLA-4 gene A-G polymorphism (IDDM12 locus) with acute-onset and insulin-depleted IDDM as well as autoimmune thyroid disease (Graves' disease and Hashimoto's thyroiditis) in the Japanese population. 53 62
9421386 1998
350
Serum concentration of soluble Fas in patients with autoimmune thyroid diseases. 53 62
9492152 1998
351
[Thyroglobulin assay ambiguities]. 53 62
9754221 1998
352
Methimazole therapy in Graves' disease influences the abnormal expression of CD69 (early activation antigen) on T cells. 53 62
9487994 1997
353
CTLA4 gene polymorphism confers susceptibility to Graves' disease in Japanese. 53 62
9459626 1997
354
Codon 17 polymorphism of the cytotoxic T lymphocyte antigen 4 gene in Hashimoto's thyroiditis and Addison's disease. 53 62
9398726 1997
355
Constitutively active germline mutation of the thyrotropin receptor gene as a cause of congenital hyperthyroidism. 53 62
9427897 1997
356
Expression, localization, and thyrotropin regulation of cathepsin D in human thyroid tissues. 53 62
9329373 1997
357
[Gene expression of thyrotropin receptor, thyroid peroxidase and thyroglobulin in autoimmune thyroid disease]. 53 62
10436985 1997
358
Expression of membrane and soluble intercellular adhesion molecule-1 in Graves' disease. 53 62
9343311 1997
359
Cytokines and Graves' disease. 53 62
9532335 1997
360
Immunoprecipitation of melanogenic enzyme autoantigens with vitiligo sera: evidence for cross-reactive autoantibodies to tyrosinase and tyrosinase-related protein-2 (TRP-2). 53 62
9328128 1997
361
Clinical validity of intercellular adhesion molecule-1 (ICAM-1) and TSH receptor antibodies in sera from patients with Graves' disease. 53 62
9385458 1997
362
[Bone metabolism markers in patients with Basedow-Graves disease]. 53 62
9380378 1997
363
Human B cells secreting immunoglobulin G to glutamic acid decarboxylase-65 from a nondiabetic patient with multiple autoantibodies and Graves' disease: a comparison with those present in type 1 diabetes. 53 62
9253351 1997
364
Coexpression of CD40 and class II antigen HLA-DR in Graves' disease thyroid epithelial cells. 53 62
9245555 1997
365
Detection of tyrosinase autoantibodies in patients with vitiligo using 35S-labeled recombinant human tyrosinase in a radioimmunoassay. 53 62
9204957 1997
366
Regulation of intercellular adhesion molecule-1 expression in human thyroid cells in vitro and human thyroid tissue transplanted to the nude mouse in vivo: role of Graves' immunoglobulins and human thyrotropin receptor. 53 62
9215271 1997
367
Engineering the human thyrotropin receptor ectodomain from a non-secreted form to a secreted, highly immunoreactive glycoprotein that neutralizes autoantibodies in Graves' patients' sera. 53 62
9228077 1997
368
Analysis of human thyrotropin receptor gene expression and immunoreactivity in human orbital tissue. 53 62
9225723 1997
369
Expression of nitric oxide synthase III in human thyroid follicular cells: evidence for increased expression in hyperthyroidism. 53 62
9225730 1997
370
Analysis of IL-2 and IL-6 binding to peripheral blood lymphocytes in Graves disease: relationship with disease activity. 53 62
9222097 1997
371
[Polymorphism of the 52 triplet gene (nucleotide 253) of the TSH receptor in Basedow-Graves patients and in healthy controls]. 53 62
9265143 1997
372
Purification and crystallisation of the autoantigen thyroid peroxidase from human Graves' thyroid tissue. 53 62
9177277 1997
373
A CTLA-4 gene polymorphism is associated with both Graves disease and autoimmune hypothyroidism. 53 62
9231050 1997
374
Polymorphisms of tumor necrosis factor receptor 2 are not associated with insulin-dependent diabetes mellitus or Graves' disease. 53 62
9174153 1997
375
Activation of CD8+ T lymphocytes in insulin-dependent diabetes mellitus. 53 62
9073547 1997
376
Differential effects of human interferon alpha and interferon gamma on xenografted human thyroid tissue in severe combined immunodeficient mice and nude mice. 53 62
9069581 1997
377
[TSH-receptor antibodies in thyroid diseases]. 53 62
9333770 1997
378
21-hydroxylase autoantibodies in adult patients with endocrine autoimmune diseases are highly specific for Addison's disease. Belgian Diabetes Registry. 53 62
9030873 1997
379
No association between a thyrotropin receptor gene polymorphism and Graves' disease in the female population. 53 62
9086566 1997
380
Systemic bias of cytokine production toward cell-mediated immune regulation in IDDM and toward humoral immunity in Graves' disease. 53 62
9000700 1997
381
TSH receptor transcripts and TSH receptor-like immunoreactivity in orbital and pretibial fibroblasts of patients with Graves' ophthalmopathy and pretibial myxedema. 53 62
9086563 1997
382
Ultrastructural localization of IgG and TPO in autoimmune thyrocytes referring to the transcytosis of IgG and the antigen presentation of TPO. 53 62
9062796 1997
383
Cytokine profiles of in vivo activated thyroid-infiltrating T cells cloned in the presence or absence of interleukin 4. 53 62
9546811 1997
384
Polymorphisms of TAP1 and TAP2 genes in Graves' disease. 53 62
9027960 1997
385
Characterisation of the antibody response to the extracellular region of recombinant thyrotropin receptor. 53 62
9546816 1997
386
The full length and splice variant thyrotropin receptor is expressed exclusively in skeletal muscle of extraocular origin: a link to the pathogenesis of Graves' ophthalmopathy. 53 62
9015347 1997
387
CTLA4 alanine-17 confers genetic susceptibility to Graves' disease and to type 1 diabetes mellitus. 53 62
8989248 1997
388
Fetal cord blood sampling in the diagnosis and the treatment of fetal hyperthyroidism in the offsprings of a euthyroid mother, producing thyroid stimulating immunoglobulins. 53 62
9436485 1997
389
TSH-receptor expression and human thyroid disease: relation to clinical, endocrine, and molecular thyroid parameters. 53 62
9001192 1996
390
Plasma selectin levels in patients with Graves' disease. 53 62
9075611 1996
391
Lack of an association between alleles of interleukin-1 alpha and interleukin-1 receptor antagonist genes and Graves' disease in a North American Caucasian population. 53 62
8954062 1996
392
IFN-gamma has a protective role against thyroid-specific autoantibody production in severe combined immunodeficient (SCID) mice xenografted with Graves' thyroid tissue. 53 62
8936668 1996
393
In vivo and in vitro evidence for iodide regulation of major histocompatibility complex class I and class II expression in Graves' disease. 53 62
8855812 1996
394
Induction of Graves-like disease in mice by immunization with fibroblasts transfected with the thyrotropin receptor and a class II molecule. 53 62
8855311 1996
395
Analysis of the thyrotropin receptor as a candidate gene in familial Graves' disease. 53 62
8855789 1996
396
Soluble intercellular adhesion molecule-1 concentrations in patients with subacute thyroiditis and in patients with Graves' disease with or without ophthalmopathy. 53 62
8980891 1996
397
[Diagnostic value of thyroid antibodies]. 53 62
8966023 1996
398
Immunoglobulins from Graves' disease patients stimulate phospholipase A2 and C systems in FRTL-5 and human thyroid cells. 53 62
8890723 1996
399
Type 2 iodothyronine deiodinase is highly expressed in human thyroid. 53 62
8770868 1996
400
An Mse I RFLP in the human CTLA4 promotor. 53 62
8780695 1996
401
Multivariate analysis of HLA loci in conjunction with a thyrotropin receptor codon 52 polymorphism in conferring risk of Graves' disease. 53 62
8875744 1996
402
Antibody to gp39, the ligand for CD40 significantly inhibits the humoral response from Graves' thyroid tissues xenografted into severe combined immunodeficient (SCID) mice. 53 62
8875745 1996
403
Antibody-dependent cell-mediated cytotoxicity in autoimmune thyroid disease: relationship to antithyroperoxidase antibodies. 53 62
8675583 1996
404
The CTLA-4 gene region of chromosome 2q33 is linked to, and associated with, type 1 diabetes. Belgian Diabetes Registry. 53 62
8817351 1996
405
Cloning and analysis of IgG kappa and IgG lambda anti-thyroglobulin autoantibodies from a patient with Hashimoto's thyroiditis: evidence for in vivo antigen-driven repertoire selection. 53 62
8752947 1996
406
Activated and interferon-gamma producing thyroid-derived T cells are detected in Graves' disease, thyroid autonomy as well as in non-toxic multinodular goiter. 53 62
8765975 1996
407
Functional expression of thyrotropin receptor in differentiated 3T3-L1 cells: a possible model cell line of extrathyroidal expression of thyrotropin receptor. 53 62
8660370 1996
408
[An immunohistochemical study on human leucocyte antigen-DR in Hashimoto thyroiditis and Graves disease]. 53 62
9387612 1996
409
Serum immunoglobulin E and soluble CD23 in patients with Graves' disease. 53 62
8926012 1996
410
Binding of antithyrotropin receptor autoantibodies in Graves' disease serum to nascent, in vitro translated thyrotropin receptor: ability to map epitopes recognized by antibodies. 53 62
8636291 1996
411
Methimazole has no dose-related effect on the serum concentrations of soluble class I major histocompatibility complex antigens, soluble interleukin-2 receptor, and beta 2-microglobulin in patients with Graves' disease. 53 62
8777381 1996
412
Human self-reactive T cell clones expressing identical T cell receptor beta chains differ in their ability to recognize a cryptic self-epitope. 53 62
8627148 1996
413
Vitiligo and Graves' disease following treatment of malignant melanoma with recombinant human interleukin 4. 53 62
8726651 1996
414
Autoimmunity to the thyroid stimulating hormone receptor. 53 62
9183516 1996
415
Elevated serum levels of macrophage-derived cytokines precede and accompany the onset of IDDM. 53 62
8720604 1996
416
Iodide, cytokines and TSH-receptor expression in Graves' disease. 53 62
8981006 1996
417
Expression of intercellular adhesion molecule-1 on human thyroid cells from patients with autoimmune thyroid disease: study of thyroid xenografts in nude and severe combined immunodeficient mice and treatment with FK-506. 53 62
8530625 1995
418
Immunoglobulin A class fibroblast antibodies in patients with Graves' disease and pretibial myxedema. 53 62
8530579 1995
419
A thyroid hormone receptor beta gene polymorphism associated with Graves' disease. 53 62
8748133 1995
420
Expression of vascular adhesion molecules on human endothelia in autoimmune thyroid disorders. 53 62
7586686 1995
421
Messenger RNA expression for a TSH receptor variant in the thymus of a two-year-old child. 53 62
8751142 1995
422
[Adenosine deaminase isoenzymes in patients with Graves' disease]. 53 62
8531390 1995
423
Intercellular adhesion molecule-1 (ICAM-1) in the sera of patients with Graves' disease: correlation with disease activity and treatment status. 53 62
8563475 1995
424
Autoantibodies to glutamic acid decarboxylase in patients with autoimmune thyroid disease: relation to competitive insulin autoantibodies. 53 62
8579720 1995
425
Na+, K+ ATPase activity in red cells predicts the recurrence of hyperthyroidism in patients with Graves' disease. 53 62
8719298 1995
426
Increased serum interleukin-1 beta during treatment of hyperthyroidism with antithyroid drugs. 53 62
7498238 1995
427
CD31, CD62E, and CD62P identify a specific pattern of endothelial activation in Graves' disease. 53 62
7542186 1995
428
Effect of thyrotropin-releasing hormone on serum thyroid hormones: a study in the patients with untreated and treated Graves' disease and subacute thyroiditis. 53 62
7608274 1995
429
Circulating selectins, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in hyperthyroidism. 53 62
7541802 1995
430
Behavior of soluble intercellular adhesion molecule-1 and endothelial-leukocyte adhesion molecule-1 concentrations in patients with Graves' disease with or without ophthalmopathy and in patients with toxic adenoma. 53 62
7541801 1995
431
Identification of thyroid stimulating hormone receptor-specific T cells in Graves' disease thyroid using autoantigen-transfected Epstein-Barr virus-transformed B cell lines. 53 62
7615799 1995
432
Cloning and functional expression of a thyrotropin receptor cDNA from rat fat cells. 53 62
7738021 1995
433
Antibodies to acetylcholinesterase cross-reacting with thyroglobulin in myasthenia gravis and Graves's disease. 53 62
7743674 1995
434
Follicular thyroid cells of autoimmune thyroiditis may coexpress ICAM-1 (CD54) and its natural ligand LFA-1 (CD11a/CD18). 53 62
7751500 1995
435
Activation of T lymphocyte subsets by synthetic TSH receptor peptides and recombinant glutamate decarboxylase in autoimmune thyroid disease and insulin-dependent diabetes. 53 62
7714099 1995
436
Thyroid cell survival in coculture with autologous peripheral or intrathyroidal lymphocytes. 53 62
7750192 1995
437
Restriction fragment length polymorphism of the T cell receptor beta-chain gene in Chinese patients with thyrotoxic hypokaleamic periodic paralysis and Graves' disease. 53 62
8852514 1995
438
Productivity of thyroglobulin and thyroid hormone on human thyroid cell in collagen gel culture. 53 62
7487672 1995
439
Endogenous antigen presentation by autoantigen-transfected Epstein-Barr virus-lymphoblastoid cells: T cell receptor N-region hydrophobicity relates to thyroid antigen recognition. 53 62
8852512 1995
440
CTLA-4 gene polymorphism associated with Graves' disease in a Caucasian population. 53 62
7829637 1995
441
T-cell reactivity to recombinant human thyrotropin receptor extracellular domain and thyroglobulin in patients with autoimmune and nonautoimmune thyroid diseases. 53 62
7829613 1995
442
Circulating intercellular adhesion molecule-1(ICAM-1) in sera of patients with Graves' disease and Hashimoto disease. 53 62
7626551 1995
443
Association of Graves' disease with an allele of the interleukin-1 receptor antagonist gene. 53 62
7530255 1995
444
Immunocytochemical localisation of interleukin-1 alpha and interleukin-6 in thyroid tissues from patients with neoplastic or autoimmune thyroid disorders. 53 62
7578871 1995
445
Tryptic peptides of human thyroglobulin: II. Immunoreactivity with sera from patients with thyroid diseases. 53 62
7527743 1994
446
Soluble endothelium-associated adhesion molecules in patients with Graves' disease. 53 62
7525128 1994
447
Increased insulin-like growth factor-1 receptors in thyroid tissues of Graves' disease. 53 62
7633196 1994
448
Studies of human peripheral blood mononuclear cells (PBMC) from patients with subacute thyroiditis in severe combined immunodeficient (SCID) mice: less production of human interferon gamma than that seen for Graves' disease. 53 62
7835825 1994
449
Thyroid hormone autoantibodies in patients with Graves' disease: effect of anti-thyroid drug treatment. 53 62
7988028 1994
450
T lymphocyte activation in Graves' disease. 53 62
7995258 1994
451
Immunoreactivity of multiple molecular forms of human thyroglobulin. 53 62
8020185 1994
452
Effects of interleukins on EGF-stimulated growth promotion in human thyroid cells: differential modifications by IL-2 and IL-6 in Graves' and normal thyroid cells. 53 62
7949016 1994
453
Transfection of thyroid autoantigens into EBV-transformed B cell lines. Recognition by Graves' disease thyroid T cells. 53 62
8189073 1994
454
Immunohistochemical demonstration of thyroid peroxidase (TPO) in human thyroid tissues from various thyroid diseases. 53 62
8067701 1994
455
Intrathyroidal cytokine gene expression profiles in autoimmune thyroiditis. 53 62
8046301 1994
456
[Long-term evolution of immunologic and thyroid function in Graves disease according different therapeutic options]. 53 62
7516033 1994
457
Recombinant thyroid peroxidase autoantibodies can be used for epitopic "fingerprinting" of thyroid peroxidase autoantibodies in the sera of individual patients. 53 62
7512572 1994
458
Isolation of thyroid peroxidase from patients with Graves' disease and comparison with animal peroxidases. 53 62
8187932 1994
459
Inhibitory effect of FK506 on intercellular adhesion molecule-1 (ICAM-1) expression on cultured thyroid cells. 53 62
7526029 1994
460
The expression of adhesion molecules in thyroid glands from patients with Graves' disease. 53 62
7519914 1994
461
The presence of higher levels of thyroglobulin, but not thyroid autoantibodies, in the thyroid vein in Graves' disease. 53 62
7911812 1994
462
Immunoregulation in autoimmune thyroid disease. 53 62
7833679 1994
463
Loss of variability in Graves' disease: stimulatory TSH-receptor antibodies bind to the TSH-receptor in a continued, non-pulsatile and non-chaotic fashion. 53 62
7924634 1994
464
Soluble intercellular adhesion molecule-1 (sICAM-1) in Graves' disease. 53 62
7866729 1994
465
[Humoral autoimmunity markers in autoimmune endocrine diseases]. 53 62
7742656 1994
466
Epitopes on thyroglobulin: a study of patients with thyroid disease. 53 62
7528064 1994
467
An analysis of the structure and antigenicity of different forms of human thyroid peroxidase. 53 62
7919999 1994
468
Differentiation of postpartum thyrotoxicosis by serum thyroglobulin: usefulness of a new multisite immunoradiometric assay. 53 62
7833663 1994
469
Proliferative responses of peripheral blood mononuclear cells from patients with Graves' disease to synthetic peptides epitopes of human thyrotropin receptor. 53 62
7519915 1994
470
[Intrathyroidal lymphocytes in autoimmune thyroid diseases]. 53 62
8066339 1994
471
Heterogeneity in cellular and antibody responses against thyrotropin receptor in patients with Graves' disease detected using synthetic peptides. 53 62
7512341 1993
472
A heritable point mutation in an extracellular domain of the TSH receptor involved in the interaction with Graves' immunoglobulins. 53 62
8268237 1993
473
Intercellular adhesion molecule-1 (ICAM-1) in Graves' disease: contrast between in vivo and in vitro results. 53 62
7902787 1993
474
FK506 inhibits phytohemagglutinin-, but not interferon-gamma-, induced HLA-DR antigen expression and accessory cell function on primary cultured human thyroid cells. 53 62
7509103 1993
475
Inhibitory effects of nicotinamide on intercellular adhesion molecule-1 expression on cultured human thyroid cells. 53 62
7903279 1993
476
Xenogeneic thyroid-stimulating hormone-like activity of the human natural anti-Gal antibody. Interaction of anti-Gal with porcine thyrocytes and with recombinant human thyroid-stimulating hormone receptors expressed on mouse cells. 53 62
8104224 1993
477
Interferon-gamma inhibition of human thyrotropin receptor gene expression. 53 62
8408457 1993
478
Studies of restriction fragment length polymorphism (RFLP) of DR and DQ genes in HLA-DR3 positive patients with Graves' disease or systemic lupus erythematosus. 53 62
7903231 1993
479
Differential autoantibody responses to thyroid peroxidase in patients with Graves' disease and Hashimoto's thyroiditis. 53 62
8408460 1993
480
Reduced activation of suppressor T lymphocytes by specific antigens in autoimmune thyroid disease. 53 62
8258649 1993
481
Estrogen receptors and cathepsin D in human thyroid tissue. 53 62
8364879 1993
482
In vitro effects of cytokines and human thyroglobulin on the induction of antibody-secreting cells in patients with auto-immune thyroid disease. 53 62
8306534 1993
483
Tissue specificity and serologic reactivity of an autoantigen associated with autoimmune thyroid disease. 53 62
8345048 1993
484
Cloning from the thyroid of a protein related to actin binding protein that is recognized by Graves disease immunoglobulins. 53 62
8327473 1993
485
Deregulated production of interleukin-4 (IL4) in autoimmune thyroid disease assayed with a new radioimmunoassay. 53 62
8222259 1993
486
A thyroid cancer specific monoclonal antibody which recognizes cryptic epitope(s) of human thyroglobulin. 53 62
7688705 1993
487
Use of Epstein-Barr virus-based vectors for expression of thyroid auto-antigens in human B-lymphoblastoid cell lines. 53 62
8397716 1993
488
T cell receptor beta chain gene polymorphisms in Graves' disease. 53 62
8101679 1993
489
Serum testosterone fractions in women: normal and abnormal clinical states. 53 62
8492720 1993
490
The thyrotrophin hormone receptor of Graves' disease: overexpression of the extracellular domain in insect cells using recombinant baculovirus, immunoaffinity purification and analysis of autoantibody binding. 53 62
8484862 1993
491
Rapid and simple subtyping of the HLA-DRB3 gene in Graves' disease by using temperature-gradient gel electrophoresis. 53 62
8320138 1993
492
Study of induction of activation of human peripheral blood mononuclear cells with a non-activating form of anti-CD3 MoAb in autoimmune thyroid disease (AITD). 53 62
8443962 1993
493
Autoimmune T-cell recognition sites of human thyrotropin receptor in Graves' disease. 53 62
8472870 1993
494
Detection of thyroid-stimulating antibody using Chinese hamster ovary cells transfected with cloned human thyrotropin receptor. 53 62
8094393 1993
495
Analysis of autoantibody reactivity in patients with Graves' disease using recombinant extracellular domain of the human thyrotropin receptor and synthetic peptides. 53 62
8136456 1993
496
Expression of the Hermes-1 (CD44) and ICAM-1 (CD54) molecule on the surface of thyroid cells from patients with Graves' disease. 53 62
7509669 1993
497
Sensitization of T lymphocytes to thyroglobulin and thyroperoxidase in autoimmune thyroid diseases. 53 62
8102254 1993
498
Crucial role of serum human chorionic gonadotropin for the aggravation of thyrotoxicosis in early pregnancy in Graves' disease. 53 62
8257857 1993
499
Is TPO detectable in the circulation? 53 62
8257863 1993
500
IgA class thyroid peroxidase and thyroglobulin autoantibodies in Graves' disease: association with the male sex. 53 62
7910048 1993
501
Enhanced expression of complement regulatory proteins on thyroid epithelial cells of Graves' disease. 53 62
1279944 1992
502
HLA-DRB3 gene alleles in Caucasian patients with Graves' disease. 53 62
1450621 1992
503
[Analysis of circulating thyroid-stimulating activities in pregnant women with Graves' disease: differential measurement of activities induced by TSH receptor antibody and hCG]. 53 62
1434029 1992
504
Heterogeneous responses of recombinant human thyrotropin receptor to immunoglobulins from patients with Graves' disease. 53 62
1354957 1992
505
Serum concentrations of osteocalcin in patients with hyperthyroidism, hypothyroidism and subacute thyroiditis. 53 62
1447487 1992
506
The expression and role in T cell adhesion of LFA-3 and ICAM-2 on human thyroid cells. 53 62
1376653 1992
507
Adhesion molecule expression in Graves' thyroid glands; potential relevance of granule membrane protein (GMP-140) and intercellular adhesion molecule-1 (ICAM-1) in the homing and antigen presentation processes. 53 62
1378365 1992
508
Mapping of a linear autoantigenic epitope within the human thyroid peroxidase using recombinant DNA techniques. 53 62
1379223 1992
509
Immunohistochemical detection and localization of a 72-kilodalton heat shock protein in autoimmune thyroid disease. 53 62
1548334 1992
510
Interactions between the immune system and the thyroid. Regulatory networks in health and disease. 53 62
1284333 1992
511
T-lymphocyte activation in adult-onset idiopathic hypoparathyroidism. 53 62
1348395 1992
512
Expression of a human thyrotrophin receptor fragment in Escherichia coli and its interaction with the hormone and autoantibodies from patients with Graves' disease. 53 62
1515018 1992
513
Function of DR-positive thyrocytes from patients with Graves' disease: quantitative analysis of thyroid peroxidase content by fluorescent photometry. 53 62
1740495 1992
514
Thyroid peroxidase antibodies in children with autoimmune thyroiditis. 53 62
1541688 1992
515
Expression of intercellular adhesion molecule-1 in thyroid follicular cells in autoimmune, non-autoimmune and neoplastic diseases of the thyroid gland: discordance with HLA. 53 62
1348415 1992
516
Is soluble CD25 antigen (interleukin-2 receptor) a useful parameter for differential diagnosis of thyrotoxicosis? 53 62
1600337 1992
517
Tumor necrosis factor beta gene polymorphisms in Graves' disease. 53 62
1346144 1992
518
The use of the amplifiable high-expression vector pEE14 to study the interactions of autoantibodies with recombinant human thyrotrophin receptor. 53 62
1312488 1992
519
Peroxidase and coupling activities of thyroid peroxidase in benign and malignant thyroid tumor tissues. 53 62
1422230 1992
520
An autoimmuno-dominant thyroglobulin epitope characterized by a monoclonal antibody. 53 62
1373164 1992
521
Assessment of thyroid function during pregnancy. 53 62
1525567 1992
522
Asialoagalacto-human chorionic gonadotropin, a carbohydrate-modified variant of human chorionic gonadotropin, antagonizes the stimulatory actions of bovine thyroid-stimulating hormone on thyroid function and HLA-DR expression in human thyroid in vitro and in vivo. 53 62
1752954 1991
523
Changes in serum thyroglobulin and thyroid autoantibodies in patients with Graves' disease treated with antithyroid drug and their relationship to relapse. 53 62
1724781 1991
524
T cell responses to synthetic thyroid peroxidase peptides in autoimmune thyroid disease. 53 62
1717189 1991
525
Comparison of thyroperoxidase and microsomal antibody assays in sera from patients with Graves disease. 53 62
1914184 1991
526
Autoantibody stimulation of the human thyrotropin receptor: regulation of adenylate cyclase activity, thyroglobulin and thyroid peroxidase mRNA levels in primary cultures of Graves' thyroid tissue. 53 62
1914236 1991
527
Thyroperoxidase, but not the thyrotropin receptor, contains sequential epitopes recognized by autoantibodies in recombinant peptides expressed in the pUEX vector. 53 62
1716261 1991
528
High levels of serum soluble interleukin-2 receptors in hyperthyroid patients: correlation with serum thyroid hormones and independence from the etiology of the hyperthyroidism. 53 62
1909702 1991
529
Thyrotropin receptor non-mediated thyroid stimulating immunoglobulin in Graves' disease. 53 62
1656957 1991
530
Increased soluble interleukin 2 receptor levels in autoimmune thyroid disease. 53 62
1683085 1991
531
Thyrotropin receptor antibody activities significantly correlate with the outcome of radioiodine (131I) therapy for hyperthyroid Graves' disease. 53 62
1687028 1991
532
Soluble interleukin-2 receptor in sera of patients with Graves' disease. 53 62
1777014 1991
533
Increased induction of HLA-DR by interferon-gamma in cultured fibroblasts derived from patients with Graves' ophthalmopathy and pretibial dermopathy. 53 62
1906894 1991
534
Effects of recombinant human interleukin-2 and tumor necrosis factor-alpha with or without interferon-gamma on human thyroid tissues from patients with Graves' disease and from normal subjects xenografted into nude mice. 53 62
1902846 1991
535
HLA-DR3 and variations of the T cell receptor beta gene in Graves' disease. 53 62
1676865 1991
536
Immunohistochemical study of thyroid peroxidase in normal, hyperplastic, and neoplastic human thyroid tissues. 53 62
1710535 1991
537
Cloning and sequencing of a novel 64-kDa autoantigen recognized by patients with autoimmune thyroid disease. 53 62
2026759 1991
538
The autoimmune infiltrate of Basedow's disease: analysis of clonal level and comparison with Hashimoto's thyroiditis. 53 62
1680724 1991
539
Unlike thyrotropin, thyroid-stimulating antibodies do not activate phospholipase C in human thyroid slices. 53 62
1673689 1991
540
The measurement of complement fixation by autoantibodies directed against thyroid membrane antigens. 53 62
1668285 1991
541
Heat shock protein 70 (HSP70) and complement C4 genotypes in patients with hyperthyroid Graves' disease. 53 62
1673096 1991
542
Expression of intercellular adhesion molecule-1 (ICAM-1) on thyroid epithelial cells in Hashimoto's thyroiditis but not in Graves' disease or papillary thyroid cancer. 53 62
1671565 1991
543
Change of circulating thyroid autoantibody titers in Graves' hyperthyroidism after antithyroid drugs therapy. 53 62
1705860 1991
544
Dynamic changes in soluble interleukin-2 receptor levels during treatment of Graves' disease. Correlation with disease activity. 53 62
1916654 1991
545
Serum thyroid-stimulating antibody, thyroglobulin levels, and thyroid suppressibility measurement as predictors of the outcome of combined methimazole and triiodothyronine therapy in Graves' disease. 53 62
1688155 1991
546
Binding of peripheral blood and thyroidal T lymphocytes to thyroid cell monolayers: possible role of "homing-like" receptors in the pathogenesis of thyroid autoimmunity. 53 62
1756223 1991
547
Increased level of soluble interleukin-2 receptor in sera of patients with Graves' disease. 53 62
1760523 1991
548
Soluble interleukin-2 receptor in sera of patients with Graves' disease. 53 62
1813855 1991
549
Peripheral blood T lymphocyte sensitization to thyroid microsomal antigen from patients with Graves' disease negative for circulating anti-thyroid microsomal antibodies. 53 62
2078913 1990
550
Effects of recombinant human interferon gamma on human thyroid tissues from patients with Graves' disease and normal subjects transplanted into nude mice. 53 62
2128634 1990
551
Expression of intercellular adhesion molecule-1 and lymphocyte function-associated antigen-3 on human thyroid epithelial cells in Graves' and Hashimoto's diseases. 53 62
1708262 1990
552
Thyroid autoantigens and human T cell responses. 53 62
2242608 1990
553
Geographical distribution of subclinical autoimmune thyroid disease in Britain: a study using highly sensitive direct assays for autoantibodies to thyroglobulin and thyroid peroxidase. 53 62
2256432 1990
554
Two cases of Graves' disease with antithyroid hormone antibodies: implication on the role of thyroglobulin as an antigen. 53 62
2096159 1990
555
Changes in thyroid volume during antithyroid drug therapy for Graves' disease and its relationship to TSH receptor antibodies, TSH and thyroglobulin. 53 62
1978459 1990
556
Implication of the HLA-DRB3 gene in Graves' disease: predominance of allele Dw24. 53 62
1979072 1990
557
Serum interferon gamma levels in autoimmune thyroid disease. 53 62
2125901 1990
558
In vitro production of interferon-gamma by peripheral blood from patients with Graves' disease, Hashimoto's thyroiditis and rheumatoid arthritis. 53 62
1976464 1990
559
Serum soluble interleukin 2 receptor in hyperthyroid Graves' disease and effect of carbimazole therapy. 53 62
2253407 1990
560
[The presence of antithyroid antibodies in the blood serum of patients with diffuse toxic goiter before and during treatment]. 53 62
2080137 1990
561
Induction of human thyroid cell ICAM-1 (CD54) antigen expression and ICAM-1-mediated lymphocyte binding. 53 62
1973649 1990
562
Serum thyroglobulin concentration as an indicator for assessing thyroid stimulation in patients with Graves' disease during antithyroid drug therapy. 53 62
2166430 1990
563
Evidence for an alternate splicing in the thyroperoxidase messenger from patients with Graves' disease. 53 62
2383265 1990
564
[The prognostic application of thyroid volume determination in patients with Graves' disease]. 53 62
1696557 1990
565
Purification and characterization of a large, tryptic fragment of human thyroid peroxidase with high catalytic activity. 53 62
2327790 1990
566
Molecular cloning of a human thyrotropin receptor cDNA fragment. Use of highly degenerate, inosine containing primers derived from aligned amino acid sequences of a homologous family of glycoprotein hormone receptors. 53 62
2358066 1990
567
Epidermal growth factor receptors and adenylate cyclase activity in human thyroid tissues. 53 62
2368445 1990
568
Changes in serum autoantibodies to thyroid peroxidase during antithyroid drug therapy for Graves' disease. 53 62
2171921 1990
569
[Thyroid peroxidase]. 53 62
2195199 1990
570
Effects of monensin on subcellular structure, thyroglobulin secretion and peroxidase activity of cultured thyroid cells obtained from patients with hyperthyroidism. 53 62
2360457 1990
571
Thyroglobulin synthesis of oxyphilic cells in various types of neoplastic and autoimmune thyroid diseases. 53 62
1698387 1990
572
Cytokines, thyroid autoantibody synthesis and thyroid cell survival in culture. 53 62
2107049 1990
573
[The effects of HLA class II genes on the susceptibility to autoimmune thyroid diseases]. 53 62
2328940 1990
574
Changes in thyroglobulin release-stimulating activity (Tg-RSA) in immunoglobulin G from patients with Graves' disease during therapy with thionamide drug. 53 62
1974494 1990
575
Triiodothyronine autoantibodies in Graves' disease: their changes after antithyroid therapy and relationship with the thyroglobulin antibodies. 53 62
1689529 1990
576
Human thyroid cells transfected with SV40 DNA retain the TSH receptor. 53 62
2170263 1990
577
The effect of carbimazole therapy on interleukin 2, interleukin 2 receptors and free radicals. 53 62
2129783 1990
578
HLA class I and II antigens in South African blacks with Graves' disease. 53 62
2293909 1990
579
Binding of bovine and porcine pituitary glycoprotein hormone alpha-subunit to TSH antibody in serum of patients with Graves' disease. 53 62
1717006 1990
580
Changes in the properties of the thyrotropin receptor antibody in patients with Graves' disease after radioiodine treatment. 53 62
1980206 1990
581
Thyroid autoimmunity and thyroid autonomy. 53 62
2202187 1990
582
The measurement of the serum sex-hormone binding globulin in various thyroid diseases. 53 62
2280997 1990
583
Brown adipose tissue influences adiponectin and thyroid hormone changes during Graves' disease therapy. 62
35894647 2022
584
Postradioiodine Graves' management: The PRAGMA study. 62
35274331 2022
585
Current concepts regarding Graves' orbitopathy. 62
35604323 2022
586
Spatiotemporal variation of childhood hyperthyroidism: a 10-year nationwide study. 62
36074933 2022
587
Efficacy of tocilizumab in anti- N -methyl-d-asparate receptor encephalitis with Graves' hyperthyroidism and positive anti-glial fibrillary acidic protein antibodies. 62
36028930 2022
588
Identification of two potential immune-related biomarkers of Graves' disease based on integrated bioinformatics analyses. 62
35962894 2022
589
Circular RNA profile in Graves' disease and potential function of hsa_circ_0090364. 62
36018563 2022
590
Identification of patients with Graves' disease who benefit from high-dose radioactive iodine therapy. 62
35972673 2022
591
Thicknesses of the retinal layers in patients with Graves' disease with or without orbitopathy. 62
35551579 2022
592
The correlation of the neutrophil-lymphocyte ratio to clinical and imaging parameters in patients with thyroid eye disease. 62
36099552 2022
593
Thyroid-Stimulating Hormone, Age, and Tumor Size are Risk Factors for Progression During Active Surveillance of Low-Risk Papillary Thyroid Microcarcinoma in Adults. 62
36182976 2022
594
Thyroid-Stimulating Antibody/Thyroid-Stimulating Hormone Receptor Antibody Ratio as a Sensitive Screening Test for Active Graves' Orbitopathy. 62
35870804 2022
595
Dupilumab: Advances in the off-label usage of IL4/IL13 antagonist in dermatoses. 62
36219538 2022
596
Role of teprotumumab in the treatment of active moderate-to-severe Graves' orbitopathy. 62
36251768 2022
597
Thyroid dysfunction following vaccination with COVID-19 vaccines: a basic review of the preliminary evidence. 62
35347651 2022
598
Actual prevalence of hypoparathyroidism after total thyroidectomy: a health insurance claims-database study. 62
35913569 2022
599
Transient Hypocalcemia After Total Thyroidectomy: The Obesity Paradox at Work? 62
35594620 2022
600
The role of activated monocyte IFN/SIGLEC1 signalling in Graves' disease. 62
35695299 2022
601
Impact of Definitive Surgery for Graves' Disease on Adolescent Disease-Specific Quality of Life and Psychosocial Functioning. 62
36254382 2022
602
The CD14++CD16+ monocyte subset is expanded and controls Th1 cell development in Graves' disease. 62
36270470 2022
603
Total thyroidectomy is more cost-effective than radioactive iodine as an alternative to antithyroid medication for Graves' disease. 62
36208983 2022
604
Ventricular fibrillation immediately after the treatment of Graves' disease coexisting with atypical angina and long QT syndrome: a case report. 62
36184604 2022
605
Graves' disease induced by Alemtuzumab in relapsing-remitting multiple sclerosis patients: an observational study in a reference center. 62
35718853 2022
606
Comprehensive immunophenotypic analysis reveals the pathological involvement of Th17 cells in Graves' disease. 62
36207336 2022
607
[A case of ultrasound-guided microwave ablation for Graves disease]. 62
36207860 2022
608
Approach to the Patient: Management and the Long-Term Consequences of Graves' Disease in Children. 62
36184734 2022
609
Investigation of molecular interaction and conformational stability of disease concomitant to HLA-DRβ3. 62
36245311 2022
610
[Graves-Basedow disease: a cause of polycythemia in an adolescent. A case report]. 62
35680521 2022
611
Decreased serum interleukin-41/Metrnl levels in patients with Graves' disease. 62
36036749 2022
612
A case of Hashimoto's thyroiditis following Graves' disease. 62
36254153 2022
613
Presentation of concurrent thrombotic thrombocytopenic purpura and Graves' disease. 62
35867945 2022
614
Risk of thyroid dysfunction associated with mRNA and inactivated COVID-19 vaccines: a population-based study of 2.3 million vaccine recipients. 62
36229814 2022
615
Moyamoya associated with Turner syndrome in a patient with type 2 spinocerebellar ataxia-Occam's razor or Hickam's dictum: a case report. 62
36209056 2022
616
New onset or deterioration of thyroid eye disease after mRNA SARS-CoV-2 vaccines:report of 2 cases and literature review. 62
36251747 2022
617
Rituximab in the treatment of Graves' orbitopathy: latest updates and perspectives. 62
36219838 2022
618
Graves' hyperthyroidism induced pancytopenia, epilepsia and muscle weakness: A case report. 62
36254023 2022
619
High levels of thyroid hormones promote recurrence of Graves' disease via overexpression of B-cell-activating factor. 62
36097969 2022
620
Xiehuo Xiaoying decoction inhibits Tfh cell expansion and promotes Tfr cell amplification to ameliorate Graves' disease. 62
36228893 2022
621
Two Cases of Thyrotoxicosis and Euglycemic Diabetic Ketoacidosis Under Sodium-glucose Transport Protein 2 Inhibitor Treatment. 62
35370232 2022
622
Clinical features of moyamoya disease with Graves' disease: a retrospective study of 394,422 patients with thyroid disease. 62
36198616 2022
623
A systematic review and meta-analysis of the etiology and treatment patterns of thyrotoxicosis in Africa. 62
36267032 2022
624
Ruptured appendicitis with undiagnosed Graves' disease: Contrast-induced impending thyroid storm. 62
36268445 2022
625
Thyroid autoantibodies. 62
36270794 2022
626
Prediction model of Graves' disease in general clinical practice based on complete blood count and biochemistry profile. 62
35387949 2022
627
Vitamin D and bone metabolism in Graves' disease: a prospective study. 62
36166168 2022
628
Advances in the differential diagnosis of transient hyperthyroidism in pregnancy and Graves' disease. 62
36112207 2022
629
Graves' Disease Following SARS-CoV-2 Vaccination: A Systematic Review. 62
36146523 2022
630
A Case of Elephantiasic Pretibial Myxedema Successfully Treated With Intralesional Triamcinolone Acetate. 62
36259012 2022
631
Murine Thyroid IL-4 Expression Worsens Hypothyroidism on Iodine Restriction and Mitigates Graves Disease Development. 62
35881515 2022
632
Wearable Technology Leads to Initial Workup of Graves' Disease in an Adolescent Female. 62
35660129 2022
633
SARS-CoV-2 vaccination related hyperthyroidism of Graves' disease. 62
35227587 2022
634
Predictive model for Graves' ophthalmopathy in patients with new-onset Graves' disease. 62
36128837 2022
635
Thyrotoxic periodic paralysis in a patient with Graves' disease: A case report. 62
36147095 2022
636
What we know about the relationship between autoimmune thyroid diseases and gut microbiota: a perspective on the role of probiotics on pediatric endocrinology. 62
36149093 2022
637
Alemtuzumab-induced autoimmune thyroid events in patients with relapsing-remitting multiple sclerosis: A real-life and monocentric experience at a tertiary-level centre. 62
34724236 2022
638
Congenital lipoid adrenal hyperplasia with Graves' disease: A case report. 62
36159444 2022
639
Autoantibody mimicry of hormone action at the thyrotropin receptor. 62
35940205 2022
640
Graves' Disease with Thymic Hyperplasia: The Response of the Thyroid Function, Thyrotropin Receptor Autoantibody, and Thymic Size to Thiamazole Treatment. 62
35228417 2022
641
The Mediation Role of Thyrotropin Receptor Antibody in the Relationship Between Age and Severity of Hyperthyroidism in Graves' Disease. 62
36074931 2022
642
Thyrotropin receptor antagonists and inverse agonists, and their potential application to thyroid diseases. 62
36171093 2022
643
Hormone- and antibody-mediated activation of the thyrotropin receptor. 62
35940204 2022
644
Atopic dermatitis and risk of autoimmune conditions: Population-based cohort study. 62
35469843 2022
645
The role of PET/CT in thyroid autoimmune diseases. 62
35612371 2022
646
A LILRB1 variant with a decreased ability to phosphorylate SHP-1 leads to autoimmune diseases. 62
36104364 2022
647
Multifocal Fibrosing Thyroiditis: an Under-recognized Mimicker of Papillary Thyroid Carcinoma. 62
35819567 2022
648
Two Cases of Autoimmune Thyroid Disorders after COVID Vaccination in Dialysis Patients. 62
36232790 2022
649
Spectrum of thyroid disease in a single patient: A case of papillary thyroid carcinoma in a patient with Graves' disease and Hashimoto's thyroiditis. 62
36188051 2022
650
2021 Asia-Pacific Graves' Disease Consortium Survey of Clinical Practice Patterns in the Management of Graves' Disease. 62
36129592 2022
651
Changes in Glucose Intolerance after Treatment with Antithyroid Drugs in Patients with Graves' Disease Using Continuous Glucose Monitoring: A Pilot Study. 62
36171124 2022
652
A potential role of human RNASET2 overexpression in the pathogenesis of Graves' disease. 62
36180758 2022
653
Distinct clinical features of post COVID-19 vaccination early-onset Graves' disease (PoVEO GD). 62
36130234 2022
654
Time to Symptom Resolution After Total Thyroidectomy for Graves' Disease. 62
36179596 2022
655
Single-Cell Chromatin Accessibility Data Combined with GWAS Improves Detection of Relevant Cell Types in 59 Complex Phenotypes. 62
36232752 2022
656
Genetic and Environmental Contribution to the Co-Occurrence of Endocrine-Metabolic Disorders and Depression: A Nationwide Swedish Study of Siblings. 62
36128682 2022
657
MRI in the assessment of thyroid-associated orbitopathy activity. 62
36116966 2022
658
Construction of the coexpression network involved in the pathogenesis of thyroid eye disease via bioinformatics analysis. 62
36076300 2022
659
Sudden extensive bloody pleural and pericardial effusion in a subject with untreated known hypothyroidism after total thyroidectomy, triggered by pneumonia. 62
36115983 2022
660
Selenium serum levels in Grave's patients with or without thyroid ophthalmopathy. 62
36116714 2022
661
Mechanisms of immune-related differentially expressed genes in thyroid-associated ophthalmopathy based on the GEO database. 62
36172114 2022
662
Outpatient endocrine surgery practice patterns are highly variable among US endocrine surgery fellowship programs. 62
36192212 2022
663
Switching from the tablet to the powder formulation of levothyroxine corrects severe hypothyroidism in a patient with lactose intolerance. 62
35249899 2022
664
The Impact of Thyroid Diseases on Patients' Work Functioning: A Pilot Study. 62
35732036 2022
665
Novel inflammatory biomarkers in thyroid eye disease. 62
35675127 2022
666
The role and molecular mechanism of gut microbiota in Graves' orbitopathy. 62
35986869 2022
667
Subacute Thyroiditis Following SARS-CoV-2 Vaccines: Six Cases Report and Review of the Literature. 62
35318621 2022
668
HTLV, a multi organ oncovirus. 62<